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Summary 2 
 
Summary 
 
 
Target of rapamycin (TOR) is the main controller of cell growth and metabolism in response 
to nutrients, growth factors and the cellular energy status.  TOR is a serine/threonine kinase 
conserved from yeast to mammals and is found in two functionally and structurally distinct 
multi-protein complexes named TOR complex 1 (TORC1) and TORC2.  Mammalian TORC1 
(mTORC1) contains mTOR, mLST8, raptor and PRAS40, while mTORC2 contains mTOR, 
mLST8, rictor, mSin1, and PRR5. mTORC2 is activated in response to growth factors, such 
as insulin and insulin-like growth factor 1 (IGF1), and its main functions involve the regulation 
of actin cytoskeleton dynamics and phosphorylation of several AGC kinases in their 
hydrophobic motif. TORC1 is directly inhibited by the immunosuppressant and anti-cancer 
drug rapamycin, whereas TORC2 is not.  Thus, use of rapamycin provides a simple and 
straightforward method to specifically study the TORC1 signaling branch.  There is no known 
TORC2-specific inhibitor, so genetic manipulation is required to study its biological 
function(s). 
 
 This thesis describes new in vivo and in vitro functions of mTORC2.  The first part 
deals with the in vivo function of mTORC2 in adipose tissue.  The adipose tissue, in addition 
to its function as a long-term fat storage depot, also has endocrine functions, plays an 
important role in the regulation of whole body glucose and lipid metabolism and is one of the 
most insulin-responsive tissues in the body.  To study mTORC2 function in adipose tissue, 
we have generated mice that lack the mTORC2-essential component rictor specifically in 
adipose tissue.  Phenotypic characterization revealed the unexpected finding that these mice 
were larger due to an increase in lean tissue mass and that they had elevated serum IGF1 
levels.  Furthermore, the knockout mice were hyperinsulinemic, but glucose tolerant.  
Overall, these findings suggest an important role for adipose mTORC2 in controlling full body 
growth and whole body glucose metabolism.  
 The second part of this thesis describes a new in vitro function of mTORC2 in 
fibroblasts.  We have taken advantage of the raptor and rictor floxed mice to isolate mouse 
embryonic fibroblasts (MEFs), which were then used to establish inducible raptor and rictor 
knockout MEF cell lines.  After initial characterization of these two cell lines, a deeper 
analysis of the role of mTORC2 in the actin-mediated process of cell migration was 
performed.  We have found that mTORC2 is required for cell migration and for regulating the 
activity of the Rho GTPases Rac1, Cdc42, and RhoA.  We have extended this study by 
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showing that mTORC2-dependent cell migration is also required in oncogenic cells, which 
suggests that mTORC2 could have an important function in the development of cancer and 
metastasis.  
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The TOR signaling pathway 
 
Rapamycin is an antifungal metabolite that was initially isolated from soil samples from the 
Easter Island (locally known as Rapa Nui) in the 1970s and that was found to have inhibitory 
effects on cell proliferation of mammalian cells.  Further studies led to the identification of the 
TOR (target of rapamycin) kinase in the budding yeast Saccharomyces cerevisiae (Heitman 
et al., 1991).  Yeast cells bearing mutations in the TOR genes were resistant to rapamycin, 
which normally forms a complex with the peptidyl-prolyl cis/trans isomerase FKBP12 to bind 
to and inhibit the TOR kinase.  TOR is a Ser/Thr kinase and is conserved in every eukaryote 
examined so far, including yeasts, algae, slime mold, plants, worms, flies and mammals 
(Wullschleger et al., 2006).  Recently, TOR was also identified in the protozoan parasite 
Trypanosoma brucei (Barquilla et al., 2008).  The main function of TOR is the regulation of 
cell growth, and its function is critical for a cell or organism since disruption of the gene is 
lethal in all eukaryotes (Kunz et al., 1993; Long et al., 2002; Menand et al., 2002; Oldham et 
al., 2000).  For example, mice deficient for mammalian TOR (mTOR) die very early during 
embryonic development (Gangloff et al., 2004; Murakami et al., 2004).  The importance of a 
functional TOR signaling pathway is further underscored by the high incidence of the TOR 
pathway being involved in human diseases.  Dysfunctional TOR signaling is associated with 
many forms of cancer, and is linked to diseases such as tuberous sclerosis complex (TSC) 
or diabetes. 
TOR is a central controller of cell growth and is regulated in response to nutrients, 
growth factors and cellular energy status.  To fulfill its function within the cell TOR is found in 
two structurally and functionally distinct multiprotein complexes, TOR complex 1 (TORC1) 
and TORC2.  In mammals, rapamycin-sensitive TORC1 (mTORC1) contains mTOR, mLST8, 
and its specific components raptor and PRAS40 (Fonseca et al., 2007; Hara et al., 2002; Kim 
et al., 2002; Kim et al., 2003a; Loewith et al., 2002; Oshiro et al., 2007; Sancak et al., 2007; 
Thedieck et al., 2007; Vander Haar et al., 2007; Wang et al., 2007).  mTORC2 is rapamycin 
insensitive and contains mTOR, mLST8 and the specific components rictor, mSin1, and 
PRR5 (Frias et al., 2006; Jacinto et al., 2006; Jacinto et al., 2004; Pearce et al., 2007; 
Sarbassov et al., 2004; Thedieck et al., 2007; Woo et al., 2007; Yang et al., 2006). 
In the following, TOR itself and the individual complexes, along with their upstream 
regulators and downstream substrates, will be described in more detail. 
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The TOR kinase 
 
The TOR genes, TOR1 and TOR2, were initially identified in the budding yeast S. cerevisiae 
(Heitman et al., 1991), where they share 67% primary sequence identity.  While some yeasts 
and the protozoan parasite T. brucei have two TOR genes, higher eukaryotes only have a 
single TOR gene, but they all encode for a very large protein of ∼ 280 kDa in size.  The TOR 
proteins share high sequence homology among all eukaryotes and they belong to the same 
kinase family known as phosphatidylinositol kinase-related kinase (PIKK) family (Abraham, 
2001; Keith and Schreiber, 1995).  Although the TOR kinase domain resembles the catalytic 
domain of the lipid kinases phosphatidylinositol 3-kinases, TOR is a serine/threonine protein 
kinase and is the founding member of the PIKK family that includes the ATM, ATR, TOR, 
SMG-1, TRRAP and DNA-PK subfamilies of PIKKs (Abraham, 2004).   
 The TOR proteins are composed of numerous highly conserved domains (Figure I-1).  
The amino-terminal part contains a large stretch of tandem HEAT repeats.  This motif is 
common among Huntingtin, Elongation factor 3, the A subunit of PP2A and TOR.  The HEAT 
repeats are composed of 40-50 amino acids and form a structure of two tandem anti-parallel 
α-helices that are thought to mediate protein-protein interactions (Perry and Kleckner, 2003).  
Towards the carboxy-terminal domain the HEAT repeats are followed by a moderately 
conserved FAT (FRAP, ATM and TRRAP) domain, which is a shared domain of the PIKK 
family and is always found together with the highly conserved FATC (FAT C-terminus) 
domain at the very carboxy-terminal end of the protein.  The FAT and FATC domains are 
believed to interact with each other to modulate kinase activity.  Next to the FAT domain is 
the FRB (FKBP-Rapamycin Binding) domain that allows binding of the FKBP-rapamycin 
complex, thereby leading to allosteric inhibition of the kinase.  The kinase domain of the 
protein lies next to the FRB domain.  Furthermore, a repressor domain was identified in 
mTOR and comprises a region of 20 amino acids (2430-2450) located directly upstream of 
the FATC domain.  Deletion of this region results in increased TOR kinase activity (Sekulic et 
al., 2000).  This repressor domain also contains two phosphorylation sites: Thr2446 is 
phosphorylated by AMP-dependent kinase (AMPK) (Cheng et al., 2004) and Ser2448 is 
phosphorylated by the TOR substrate S6K1 (Chiang and Abraham, 2005; Holz and Blenis, 
2005).  However, the physiological meaning of these phosphorylation sites is not well 
understood.  Additionally, an autophosphorylation site was identified at Ser2481, but the 
physiological relevance is also not well defined (Peterson et al., 2000).  Only recently, it was 
suggested that this phosphorylation is specific to only one of the two complexes and 
resembles the kinase activity of the complex (Copp et al., 2009).  A schematic summary of 
the various domains within the TOR kinase is depicted in Figure I-1.   
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The abundance of several putative protein-protein interaction domains clearly suggested that 
TOR might associate with many cellular proteins.  This assumption was also supported by 
gel filtration experiments demonstrating that TOR consistently migrated in a 2 MDa complex 
(Kim et al., 2002; Loewith et al., 2002).  These ideas led to the identification of several 
binding partners of TOR that were subsequently found to define the two functionally distinct 
multiprotein complexes, TOR complex 1 (TORC1) and TORC2.  The complexes will be 
described in more detail in the next part.  
 
 
Figure I-1.  Illustration of the domain structure of mammalian TOR.   
For more details see text. 
 
 
TOR complex 1 
 
Composition and localization 
In yeast, TORC1 is comprised of either TOR1 or TOR2, LST8 (lethal with sec thirteen), 
KOG1 (kontroller of growth), and TCO89 (89-kDa subunit of TOR complex one) (Loewith et 
al., 2002; Reinke et al., 2004).  TCO89 is the only non-essential component of yeast TORC1 
and no homologue was found in higher eukaryotes.  Deletion of any other member of the 
complex is lethal in yeast (Heitman et al., 1991; Loewith et al., 2002).  Interestingly, only 
when assembled with the TORC1 components, the FKBP12-rapamycin inhibitory complex 
can bind to the FRB domain and block the activity of TOR.   
Mammalian TORC1 (mTORC1) consists of mTOR, mLST8 and the KOG1 homologue 
raptor (Hara et al., 2002; Kim et al., 2002; Kim et al., 2003a; Loewith et al., 2002).  A full 
body knockout of any component of mTORC1 in mice results in early embryonic lethality 
(Gangloff et al., 2004; Guertin et al., 2006).  mLST8 (previously also known as GβL) is a 36 
kDa protein that consists entirely of seven WD40 repeats (about 40 amino acids with 
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conserved W and D forming four anti-parallel β strands) allowing protein-protein interaction 
(Kim et al., 2003a).  The molecular function of mLST8 within mTORC1 is still ambiguous.  
Initial studies suggested that the constitutive binding of mLST8 to mTOR was important for 
the activity of mTORC1 (Kim et al., 2003a).  However, more recent findings in mLST8-/- 
mouse embryonic fibroblasts (MEFs) revealed that mLST8 is dispensable for mTORC1 
function (Guertin et al., 2006).  Also, in S. cerevisiae no clear data could be obtained on the 
role of LST8 in regulating TORC1.  raptor is a 150 kDa protein and contains a highly 
conserved amino-terminal region followed by three HEAT repeats and seven WD40 repeats.  
raptor is a positive regulator of mTOR activity and functions as a scaffold protein to couple 
mTOR to its substrates (Hara et al., 2002; Kim et al., 2003a; Schalm et al., 2003).  Inhibition 
of mTORC1 by rapamycin results in the disruption of raptor binding to mTOR (Kim et al., 
2002; Oshiro et al., 2004).  
Despite several approaches in various labs, the localization of TORC1/mTORC1 
within the cell is not clearly defined.  However, a common finding of all studies in yeast 
suggests that TORC1 associates with membranes.  Binding of TORC1 to the plasma 
membrane, vacuolar membrane and also endosomal membranes was demonstrated (Araki 
et al., 2005; Cardenas and Heitman, 1995; Chen and Kaiser, 2003; Kunz et al., 2000; Reinke 
et al., 2004; Sturgill et al., 2008; Wedaman et al., 2003), but the physiological significance of 
TORC1 association to distinct membranes is not understood, as well as the question whether 
TORC1 localization is a regulated and dynamic process.  In mammalian cells the localization 
of mTOR to endomembranes is consistent with the findings in yeast.  But mTOR localization 
also remains ambiguous as individual studies proposed different compartmental localization 
of mTOR, including mitochondrial, endoplasmic reticulum and Golgi apparatus membranes 
(Desai et al., 2002; Drenan et al., 2004).  One study even suggests a nuclear localization of 
mTOR (Bachmann et al., 2006).  Recently, new findings propose a regulated localization of 
mTOR to specific endomembranes upon activation by amino acids (Sancak et al., 2008). 
 
 
Upstream regulators of mTORC1 
mTORC1 integrates three major inputs to regulate catabolic and anabolic processes that 
collectively determine cell growth and metabolism.  Growth factors (insulin/insulin-like growth 
factor) and nutrients (amino acids) activate mTORC1, while a low cellular energy status 
inhibits mTORC1 (also see Figure I-2).   
 
Activation by insulin occurs via the well-established insulin/PI3K/Akt pathway.  Insulin binding 
to its receptor activates a cascade of phosphorylation and recruitment events leading to the 
phosphorylation and activation of Akt (also known as PKB), which then can activate 
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mTORC1 via two pathways.  The main pathway involves an inhibitory phosphorylation of the 
TSC1/TSC2 (tuberous sclerosis complex 1 and 2) complex, a GTPase activating protein 
(GAP) towards the Rheb GTPase (Garami et al., 2003; Inoki et al., 2003a; Inoki et al., 2002; 
Manning et al., 2002; Potter et al., 2002; Tee et al., 2003; Zhang et al., 2003).  When the 
TSC1/TSC2 complex is inactive Rheb is in its active GTP-bound form and can directly bind 
and activate mTORC1 (Long et al., 2005a; Long et al., 2005b; Smith et al., 2005).  However, 
the molecular mechanism of how Rheb activates mTORC1 is not clear.  Akt can further 
activate mTORC1 by an inhibitory phosphorylation of the protein PRAS40 (Proline-rich Akt 
substrate) that otherwise binds raptor and thereby inhibits mTORC1 (Fonseca et al., 2007; 
Oshiro et al., 2007; Sancak et al., 2007; Thedieck et al., 2007; Vander Haar et al., 2007; 
Wang et al., 2007). 
 
 
Figure I-2: Overview of the mTOR signaling pathway.  For more details see text. 
 
Regulation of mTORC1 by the cellular energy status also involves the TSC1/TSC2 complex.  
If energy levels (glucose availability) are low within the cell, the AMP/ATP ratio is increased 
and sensed by AMPK.  AMP directly binds to and allosterically activates AMPK to allow full 
activation of AMPK by the tumor suppressor LKB1 (Shaw et al., 2004b).  LKB1 
Introduction 11 
phosphorylates and activates AMPK, which in turn phosphorylates TSC2 and activates the 
TSC1/TSC2 complex causing inhibition of mTORC1 (Corradetti et al., 2004; Inoki et al., 
2003b; Shaw et al., 2004a).  Overall, active AMPK turns on ATP-generating catabolic 
pathways, such as fatty acid oxidation and glycolysis, and shuts off ATP-consuming anabolic 
processes, such as translation and fatty acid synthesis.   
 
The major nutritional input that regulates mTORC1 activity is the supply of amino acids.  
Amino acids, in particular leucine and arginine, are essential for mTORC1 activation, since 
insulin alone is not sufficient to activate mTORC1 (Hara et al., 1998).  The molecular 
mechanism how amino acids activate mTORC1 is not fully understood, however, several 
studies investigated single steps of mTORC1 activation to narrow down the proteins involved 
in amino acid activation of mTORC1.  In cells lacking either TSC1 or TSC2 the mTORC1 
pathway remains sensitive to amino acid starvation, suggesting that amino acids activate 
mTORC1 downstream of the TSC1/TSC2 complex (Smith et al., 2005).  Further studies 
suggested that amino acids regulate Rheb binding to mTORC1 (Long et al., 2005b).  Only 
recently, a new regulator of the mTORC1 signaling branch was identified.  The Rag proteins 
belong to the family of small GTPases and were shown to regulate mTORC1 activity in the 
presence of amino acids (Kim et al., 2008; Sancak et al., 2008).  Amino acids increase the 
binding of active Rag to mTORC1 thereby promoting the intracellular localization of mTOR to 
the proximity of its activator Rheb.  Overexpression of a constitutively active mutant of Rag 
rendered the mTORC1 branch insensitive to amino acids.   
Several other studies proposed another mechanism how amino acids signal to 
mTORC1 independent of the TSC1/TSC2-Rheb-Rag branch and they include the positive 
mTORC1 regulators hVps34 (vacuolar protein sorting 34) (Byfield et al., 2005; Nobukuni et 
al., 2005), a class III PI3 kinase, and MAP4K3 (mitogen-activated protein kinase kinase 
kinase kinase 3) (Findlay et al., 2007).   
 
Besides the three major inputs – nutrients, growth factors and cellular energy status – that 
regulate mTORC1 activity, additional pathways can influence mTORC1 signaling.  These 
include positive regulation via the Wnt signaling pathway (Inoki et al., 2006), mitogenic 
activation by the lipid second messenger phosphatidic acid (PA) (Fang et al., 2003; Fang et 
al., 2001; Ha et al., 2006; Kam and Exton, 2004; Sun et al., 2008) and negative regulation via 
cellular stresses such as hypoxia through REDD1 and 2 (Regulated in Development and 
DNA Damage Response genes 1 and 2) (Brugarolas et al., 2004; DeYoung et al., 2008; 
Reiling and Hafen, 2004). 
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Downstream effectors of mTORC1 
In mammals, mTORC1 regulates various cellular processes including ribosome biogenesis, 
translation, transcription, autophagy, and mitochondrial metabolism (Soulard and Hall, 2007).  
Despite influencing a broad range of cellular processes only two direct substrates for 
mTORC1 have been identified so far:  S6K (p70 S6 kinase) and 4E-BP1 (eIF4E-binding 
protein 1, also known as PHAS-I) (Brunn et al., 1997; Burnett et al., 1998).  Both proteins 
contain a TOS (TOR signaling) motif, a five amino acid sequence that allows binding of the 
substrates to raptor, and which is crucial for mTOR-dependent phosphorylation (Nojima et 
al., 2003; Schalm and Blenis, 2002; Schalm et al., 2003).   
 
S6K belongs to the family of AGC kinases (protein kinases A, G and C) and once activated 
phosphorylates the ribosomal protein S6 to activate translation.  S6K contains several mTOR 
phosphorylation sites, but the main site required for S6K activation is Thr389, which is 
located in the hydrophobic motif (Pearson et al., 1995).  Phosphorylation in the hydrophobic 
motif is required for interaction of S6K with phosphoinostide-dependent kinase 1 (PDK1) and 
subsequent phosphorylation and full activation by PDK1 at Thr229 in the activation loop 
(Alessi et al., 1998; Pullen et al., 1998).  The hydrophobic motif and the activation loop, along 
with the mode of activation, are common to all AGC kinases.  Several other rapamycin-
sensitive phosphorylation sites in S6K were also described (Isotani et al., 1999; Pearson et 
al., 1995; Saitoh et al., 2002). 
In addition to being a downstream effector of mTORC1 signaling S6K also has an 
important regulatory function on the upstream insulin signaling pathway, which is defined as 
the negative feedback loop.  Upon activation of mTORC1, activated S6K phosphorylates 
IRS1 at multiple inhibitory sites thereby promoting degradation of IRS (Harrington et al., 
2004; Haruta et al., 2000; Shah et al., 2004; Tremblay et al., 2007; Ueno et al., 2005; Um et 
al., 2004).  As a consequence, further Akt signaling by insulin is attenuated and cells are in 
an insulin-resistant state.   
 
4E-BP1 is a small protein (12 kDa) and negatively regulates translation initiation.  
Hypophosphorylated 4E-BP1 binds to and sequesters eIF4E (eukaryotic initiation factor 4E).  
mTORC1 phosphorylates 4E-BP1 at multiple sites and thereby causes the dissociation from 
eIF4E (Gingras et al., 1999; Gingras et al., 2001; Mothe-Satney et al., 2000).  Upon release 
from 4E-BP1, eIF4E recruits additional factors, which will finally result in the assembly of the 
small ribosomal subunit and the recruitment to the mRNA to initiate translation.  
 
Overall, upon activation mTORC1 positively regulates translation initiation via activating 
phosphorylation of S6K and inhibitory phosphorylation of 4E-BP1. 
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TOR complex 2 
 
The following part on TOR complex 2 is part of a manuscript prepared for an invited review 
for publication in TiBS (Trends in Biological Sciences).  It covers the major findings on TOR 
complex 2 in budding yeast, fission yeast, slime mold, worm, flies and mammals.  
 
 
TORC2 in budding yeast 
TOR was initially identified in the budding yeast Saccharomyces cerevisiae, in a genetic 
selection for spontaneous rapamycin resistant mutants (Heitman et al., 1991).  In contrast to 
other eukaryotes, yeast (budding and fission yeast) contains two TOR genes, TOR1 and 
TOR2.  The existence of two TORs in yeast facilitated the study of TOR signaling as it 
initially helped to identify two separate TOR signaling branches.  Biochemical studies later 
demonstrated the existence of two functionally distinct TOR complexes that correspond to 
and thereby confirm the two previously identified branches.  Whereas rapamycin-sensitive 
TORC1 contains either TOR1 or TOR2, rapamycin-insensitive TORC2 contains only TOR2 
of the two TORs.  TORC2 consists also of AVO1, AVO2, AVO3, LST8 and BIT61 (Loewith et 
al., 2002; Reinke et al., 2004) (Figure I-3a). AVO1, AVO3 and LST8 are essential, conserved 
proteins required for kinase activity.  In contrast, AVO2 and BIT61 are not essential, and no 
clear homologous counterparts have been identified so far in higher eukaryotes, although 
BIT61 and the mammalian TORC2 (mTORC2) component proline-rich protein 5 (PRR5) 
share low sequence similarity (Hayashi et al., 2007; Woo et al., 2007).  Studies investigating 
the molecular organization of TORC2 in yeast revealed that TORC2 is oligomeric, likely a 
TORC2-TORC2 dimer (Wullschleger et al., 2005).   
 Even before the two TOR complexes were identified, TOR2, but not TOR1, was 
known to regulate the cell cycle-dependent polarization of the actin cytoskeleton (Schmidt et 
al., 1996), thereby implicating TOR2, and hence later on TORC2, in the spatial control of 
yeast cell growth.  Further studies showed that the aberrant depolarization of the actin 
cytoskeleton in TORC2 temperature sensitive mutants could be suppressed by 
hyperactivation of the cell wall integrity pathway, which involves Protein Kinase C1 (PKC1).  
In fact, several genetic studies revealed that PKC1, via the Rho-like GTPases RHO1 and 
RHO2 and their GDP/GTP exchange factor ROM2, mediates TORC2 signaling to actin 
organization (Bickle et al., 1998; Helliwell et al., 1998a; Helliwell et al., 1998b; Loewith et al., 
2002; Schmidt et al., 1997).  However, further molecular details on the activation of this 
pathway required the identification of TORC2 substrates.  In 2005, Kamada et al. identified 
the first yeast TORC2 substrate, Yeast Protein Kinase 2 (YPK2) (Kamada et al., 2005).  
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YPK2 is an AGC kinase and closely related to mammalian serum and glucocorticoid induced 
protein kinase-1 (SGK1).  TORC2 activates YPK2 by directly phosphorylating Ser641 and 
Thr659 in the turn and hydophobic motifs, respectively (Figure I-3a). Recent results showed 
that TORC2 activity is also required for the phosphorylation of the turn motif in PKC1 
(Facchinetti et al., 2008), although it is unclear whether TORC2 phosphorylates PKC1 
directly.  In addition to YPK2, Slm proteins, which bind phosphatidylinositol-4,5-bisphosphate 
(PIP2), have been characterized as direct TORC2 substrates.  Slm1 and Slm2 can regulate 
actin organization independently of YPK2 (Fadri et al., 2005).  However, a constitutively 
active mutant of YPK2 suppresses the lethality provoked by the complete loss of TORC2 
(Kamada et al., 2005), suggesting that YPK2 is the main TORC2 effector.  Most TORC2 
mediated functions, including actin remodeling, are now believed to be mediated via YPK2. 
Aronova et al. (Aronova et al., 2008) recently described a new function for TORC2.  
They showed that TORC2, via YPK2, controls the sphingolipid biosynthetic pathway and 
hence mediates de novo ceramide biosynthesis.  Other studies have shown that YPK2 and 
its homologue YPK1 are also involved in regulating eisosome assembly and turnover in a 
sphingolipid-dependent manner (Luo et al., 2008).  Eisosomes are protein complexes near 
the plasma membrane involved in the early steps of endocytosis.  Whether TORC2 is also 
directly involved in the regulation of endocytosis remains to be confirmed.  Interestingly, 
GFP-tagged TOR2 localizes to punctate structures in the proximity of the plasma membrane, 
which resemble eisosomes (Sturgill et al., 2008). 
 Thus, the downstream effectors and functions of TORC2 in S. cerevisiae are coming 
into focus, the upstream regulators of TORC2 remain completely unknown. 
 
 
 TORC2 in fission yeast 
Schizosaccharomyces pombe, like S. cerevisiae, has two TOR homologues, Tor1 and Tor2.  
However, and this easily leads to confusion, fission and budding yeast TOR proteins are 
numbered in the opposite way, as the S. pombe proteins were named based on order of 
discovery rather than based on function.  Budding yeast TOR2 is the sole TOR protein found 
in TORC2, whereas in fission yeast Tor1 is the main determinant of TORC2 (Matsuo et al., 
2007), suggesting that S. pombe Tor1 is functionally equivalent to S. cerevisiae TOR2. S. 
pombe TORC2 is composed of Tor1, Sin1, Ste20, Wat1 (also known as Pop3) and Bit61 
(Figure I-3b). S. pombe Tor1 is not essential for normal growth but is required for survival 
under stress conditions, proper G1 arrest, and sexual development (Kawai et al., 2001; 
Weisman and Choder, 2001).  Surprisingly, in contrast to other organisms, rapamycin has no 
effect on normal growth in S. pombe.  Initially, rapamycin was found to affect sexual 
development; later experiments showed that Tor1-mediated amino acid uptake in fission 
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yeast is also rapamycin sensitive (Weisman et al., 1997; Weisman et al., 2001; Weisman et 
al., 2005).  As rapamycin blocks Tor1-mediated functions, it was believed that rapamycin in 
fission yeast inhibits TORC2 function.  However, Petersen and Nurse recently showed that 
rapamycin can also inhibit Tor2, and hence TORC1, but in a nutrient-dependent manner 
(Petersen and Nurse, 2007).  Currently, it remains unclear why rapamycin does not arrest 
fission yeast growth as in other eukaryotes.  Furthermore, the molecular details on how 
rapamycin inhibits TORC2 and possibly TORC1 are not well understood. 
 To identify potential substrates of fission yeast Tor1, Matsuo et al. performed a high-
copy suppressor screen of a Tor1 sterility mutant and isolated Gad8 as a potential candidate 
(Matsuo et al., 2003).  Gad8 is a Ser/Thr kinase belonging to the AGC kinase family and is 
the fission yeast homologue of YPK2 in budding yeast and SGK1 in other organisms.  
Matsuo et al. demonstrated that the activity and phosphorylation status of Gad8 depend on 
Tor1 activity.  On a molecular level, they showed that the critical Tor1 phosphorylation sites 
in Gad8 are Ser527 and Ser546, the turn and hydrophobic motif sites, respectively (Figure I-
3b). These findings contributed very early to the idea that TOR complexes regulate many 
AGC kinases. 
 
 
TORC2 in Dictyostelium 
Dictyostelium discoideum is a powerful model organism to study mechanisms of cell 
movement and chemotaxis.  This slime mold is a unicellular eukaryotic organism that, upon 
starvation, forms multicellular aggregates.  This developmental program depends on 
chemotaxis toward a high extracellular level of cyclic AMP secreted by neighboring cells.  
Lee et al. showed that the underlying mechanism of cell movement and aggregate formation 
depends on TORC2 (Lee et al., 2005).  TORC2 in D. discoideum comprises Tor, Lst8, Rip3 
(AVO1 in S. cerevisiae) and Pia (AVO3 in S. cerevisiae) (Figure I-3c), and cells deficient for 
any of these components lose speed, cell polarity and directionality, i.e., they display an 
overall defect in chemotaxis.  Furthermore, Lee et al. demonstrated that cells lacking any 
TORC2 component exhibit reduced PKBA and PKBR1 activity, two Akt (also known as 
protein kinase B) homologues and AGC kinase family members that are required to fully 
activate the chemotactic response. 
 Chemoattractant signaling triggers several cellular responses.  One well 
characterized response is the production of phosphatidylinositol 3,4,5-triphosphate (PIP3) at 
the leading edge of motile cells. It is well established that PIP3 production is an important 
step in regulating chemotaxis; however, chemotaxis still occurs in the absence of PIP3 (Chen 
et al., 2003; Hoeller and Kay, 2007), and a recent study provided insight on the molecular 
pathway regulating PIP3-independent chemotaxis.  Kamimura et al. (Kamimura et al., 2008) 
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showed that TORC2 is activated in a PIP3-independent manner by a heterotrimeric G protein 
and by cytosolic Ras GTPases.  This signaling leads to activation of the PKBs, mainly 
PKBR1, which in turn phosphorylate several downstream targets to ultimately regulate 
directed cell movement.  These findings suggest a possibly direct regulation of TORC2 by 
Ras.  This idea is further supported by the presence of a Ras-binding domain in Rip3 (Ras-
interacting protein-3), the mSin1 homologue in D. discoideum, which, when mutated, causes 
an impaired chemotactic response (Lee et al., 2005). Kamimura et al. also confirmed that 
TORC2 activity is required to phosphorylate the hydrophobic motif in PKBA and PKBR1 and 
thus to activate these AGC kinases (Lee et al., 2005).  Overall, these studies in D. 
discoideum underscore the importance of TORC2 in actin remodeling and cell movement, 
and could provide insight on the role of TORC2 in actin organization in other organisms.  D. 
discoideum might also be a particularly valuable system for unraveling the upstream 
regulation of TORC2.  So far, only very little is known about the upstream regulation of 
TORC2 in other organisms, and it would be of interest to know whether Ras-mediated 
activation of TORC2 is conserved in other organisms. 
 
 
TORC2 in worms and flies 
Recently, two independent studies have demonstrated that TORC2 is also present in the 
nematode Caenorhabditis elegans (Jones et al., 2009; Soukas et al., 2009).  Both studies 
identified CeRictor in a screen for mutants with altered lipid storage and showed that loss-of-
function mutants in CeRictor are viable, but developmentally delayed with a reduced overall 
body size (Figure I-3d).  Increased fat storage in the mutant worms suggests an important 
role for TORC2 in regulating fat metabolism.  Interestingly, an sgk1 null mutant, but not a 
mutant with impaired AKT signaling, phenocopies a CeRictor mutant, and a constitutively 
active SGK1 suppresses a CeRictor mutation.  Thus, TORC2 in worms appears to signal 
mainly through SGK1.  This, combined with findings in yeast suggesting that the SGK1 
homolog YPK2 is the main TORC2 effector, lends doubt to whether Akt is the primary 
effector of TORC2 in other eukaryotes. Loss of mTORC2 in mammals has only little effect on 
Akt activity (see below). 
 
Similar to TORC2 mutants in worms, rictor and sin1 mutants of the fly Drosophila 
melanogaster are viable, but reduced in body size (Hietakangas and Cohen, 2007; Lee and 
Chung, 2007).  Also in flies, TORC2 is the main kinase phosphorylating Akt at the 
hydrophobic motif (Figure I-3e).  Although loss of TORC2 normally causes only a mild growth 
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Figure I-3: The conserved TORC2 pathway. TORC2 structure and function are conserved 
in (a) budding yeast (S. cerevisiae),  (b) fission yeast (S. pombe), (c) slime mold (D. 
discoideum), (d) worms (C. elegans), (e) flies (D. melanogaster) and (f) mammals. In all 
organisms, TORC2 is composed of the TOR kinase (orange), LST8 (yellow), AVO3 or its 
homologue (green), and AVO1 or its homologue (brown). In S. cerevisiae, S. pombe and 
mammals, additional TORC2 components were identified (white). All shown TORC2 
substrates (blue) are members of the AGC kinase family. The AGC kinases share a 
conserved mode of regulation involving phosphorylation of their hydrophobic motif (red), turn 
motif (pink), and activation loop (gray).  TORC2 phosphorylates the hydrophobic motif in all 
shown kinases.  TORC2 has so far been shown to phosphorylate the turn motif, directly or 
indirectly, in YPK2, Gad8, and mammalian Akt and PKCα.  PDK1, which is also conserved in 
all organisms shown, phosphorylates the activation loop.  
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defect in flies, Hietakangas and Cohen (Hietakangas and Cohen, 2007; Lee and Chung, 
2007) made the interesting observation that loss of TORC2 strongly inhibits hyperplasia 
caused by elevated phosphatidylinositol-3-kinase (PI3K) signaling, suggesting that TORC2-
regulated Akt activity might be more important in conditions of elevated Akt signaling. 
 
 
TORC2 in mammals 
Mammalian TORC2 was identified in 2004.  At that time, TORC2 was known to consist of 
mTOR, mLST8 and the TORC2-specific component rictor (Jacinto et al., 2004; Sarbassov et 
al., 2004).  More recently, two additional complex-specific components were identified - the 
AVO1 homologue mSin1 (Frias et al., 2006; Jacinto et al., 2006; Yang et al., 2006), and the 
BIT61 family members PRR5 and PRR5L (also known as Protor1 and Protor2) (Pearce et 
al., 2007; Thedieck et al., 2007; Woo et al., 2007).  Except for PRR5 and PRR5L, all 
mTORC2 components are essential and knockout of any one of them in mice results in 
developmentally delayed embryos that die in midgestation around embryonic day E10.5 
(Guertin et al., 2006; Jacinto et al., 2006; Shiota et al., 2006; Yang et al., 2006).  
 Similar to TORC2 in S. cerevisiae, mTORC2 cannot be directly inhibited by 
rapamycin.  However, in a few cell lines, prolonged rapamycin treatment can inhibit mTORC2 
activity indirectly (Sarbassov et al., 2006).  In their study, Sarbassov et al. showed that long-
term rapamycin treatment prevents de novo mTORC2 assembly and thereby inhibits 
mTORC2 activity, but only in a few of the many cell lines examined.  The effect of rapamycin 
on mTORC2 assembly appears to be due to rapamycin binding free mTOR and to an indirect 
consequence of rapamycin’s inhibition of protein synthesis and thus the synthesis of new 
mTOR. 
 A recent study by Copp et al. (Copp et al., 2009) showed that mTOR is 
phosphorylated in an mTORC-specific manner.  mTOR phosphorylation at Ser2448 is 
predominantly, but not exclusively, associated with mTORC1 whereas mTOR in mTORC2 is 
specifically phosphorylated at Ser2481.  Copp et al. suggest that the mTORC2 specific 
phosphorylation at Ser2481 could be used as a biomarker for mTORC2 sensitivity to 
rapamycin.  However, to date, the functional importance of these phosphorylation sites is 
completely unknown, and it is important to point out that these sites should always be used 
along with other complex-specific readouts to definitively specify complex activation. 
 
The first function ascribed to mTORC2, based on the previously known function of TORC2 in 
yeast, is the regulation of the actin cytoskeleton.  Knockdown of mTORC2-specific 
components in cultured cells results in alteration of the actin cytoskeleton.  Furthermore, also 
as in yeast, it was suggested that mTORC2 signals to the actin cytoskeleton via 
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RhoGTPases and PKC (Jacinto et al., 2004; Sarbassov et al., 2004).  However, while two 
research groups have independently observed an altered actin cytoskeleton upon 
knockdown of mTORC2-specific components, opposite phenotypes were observed.  Jacinto 
et al. observed that mTORC2 is required for cell spreading and actin fiber assembly.  In 
contrast, the findings by Sarbassov et al. suggest that loss of mTORC2 promotes actin fiber 
assembly.  More recently, a role for mTORC2 in regulating the actin cytoskeleton was 
questioned when no obvious alterations in the actin cytoskeleton were observed in 
embryonic fibroblasts derived from rictor knockout mice (Guertin et al., 2006; Shiota et al., 
2006).  The apparent discrepancies on mTORC2-mediated actin regulation could possibly be 
related to the different systems studied. The early knockdown studies looked at actin 
changes immediately after loss of mTORC2, but used different cell lines, whereas the 
subsequent studies looked at knockout cells permanently deficient for mTORC2.  One 
possible explanation could be that cells constitutively lacking mTORC2 might adapt by using 
other mechanisms to regulate actin cytoskeletal organization.  Several other studies using 
different approaches have supported a role for mTORC2 in actin-regulated processes.  
Misregulated mTORC2 activity results in altered cell motility in various cell types, including 
different cancer cells where migration plays an important role in metastasis (Dada et al., 
2008; Liu et al., 2006; Masri et al., 2007). Overall, the molecular mechanism by which 
mTORC2 regulates the actin cytoskeleton remains unclear. 
 
In 2005, the first direct substrate of mTORC2, Akt, was identified.  mTORC2 was found to be 
a long sought-after kinase phosphorylating Ser473 in the hydrophobic motif of Akt (Figure I-
3f) (Hresko and Mueckler, 2005; Sarbassov et al., 2005).  Although earlier knockdown 
studies of rictor showed decreased phosphorylation also of Thr308 in the activation loop, 
further studies in knockout mice suggested that phosphorylation of Thr308, by 
phosphoinositide-dependent kinase 1 (PDK1), does not depend on prior Ser473 
phosphorylation (Frias et al., 2006; Guertin et al., 2006; Jacinto et al., 2006; Shiota et al., 
2006).  The independent phosphorylation of Thr308 and Ser473 contrasts with the 
hierarchical phosphorylation of Thr229 and Thr389 in S6K; phosphorylation by mTORC1 
(Thr389) is required for subsequent phosphorylation by PDK1 (Thr229) (reviewed in (Mora et 
al., 2004)).  Furthermore, rather than being inactive, Akt without Ser473 phosphorylation 
appears to remain largely active as determined by the phosphorylation state of the Akt 
substrates glycogen synthase kinase 3 (GSK3), Tuberous Sclerosis Complex protein 2 
(TSC2), Bad and the forkhead class O transcription factors 1/3a (FoxO1/3a).  Only FoxO1/3a 
and possibly Bad show decreased phosphorylation upon loss of Ser473 phosphorylation 
(Guertin et al., 2006; Jacinto et al., 2006; Yang et al., 2006).  Thus, mTORC2-mediated Akt 
phosphorylation does not seem to determine absolute activity, but rather appears to 
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determine substrate specificity.  It is also possible that under conditions of low Akt activity, 
some Akt substrates can be phosphorylated by another kinase.  For example, under 
conditions of insulin resistance when Akt is no longer active, GSK3 is phosphorylated by S6K 
(Zhang et al., 2006).  Furthermore, it has been shown that FoxO can also be phosphorylated 
by SGK1 (Brunet et al., 2001), another mTORC2 substrate, providing a possible explanation 
for why cells with reduced mTORC2 activity show reduced FoxO phosphorylation but not 
reduced GSK3 phosphorylation.  
 
Following the identification of Akt as an mTORC2 substrate, other AGC kinases were 
identified as additional substrates.  In particular, many groups focused on the 
phosphorylation of PKC.  Sarbassov et al. showed that PKCα phosphorylation (at the 
hydrophobic motif) and activity depend on mTORC2 (Sarbassov et al., 2004).  However, this 
study suggested that the control of PKCα by mTORC2 is indirect.  Ikenoue et al. (Ikenoue et 
al., 2008) and Facchinetti et al. (Facchinetti et al., 2008) later showed that mTORC2 is 
required for phosphorylation of all conventional PKCs and the novel PKCε at their 
hydrophobic motif and, in addition, at their turn motif, thereby controlling post-translational 
processing and stability of PKC (Figure I-3f).  Loss of mTORC2 activity results in a reduction 
in total protein levels of PKC. Ikenoue et al. and Facchinetti et al., also showed that mTORC2 
directly phosphorylates the turn motif in Akt.  Interestingly, only phosphorylation of the 
hydrophobic motif, but not the turn motif, of PKC and Akt occurs in a growth-factor 
dependent manner.  Overall, whether mTORC2 is the direct kinase of PKC remains an open 
question, as no study to date has been able to demonstrate direct in vitro phosphorylation of 
either site on any PKC isoform by mTORC2.  Furthermore, it remains unclear how strongly 
mTORC2 activity influences PKC-mediated signaling events. 
 
As discussed above, YPK2 and Gad8 were identified early on as TORC2 substrates, in 
budding and fission yeast, respectively.  Both AGC kinases have close homology to the 
mammalian SGK kinase family.  However, SGK1 was identified in mammals as an mTORC2 
substrate only very recently (Garcia-Martinez and Alessi, 2008).  mTORC2 phosphorylates 
SGK1 at its hydrophobic motif site (Figure I-3f) and thereby regulates SGK1’s activity toward 
its physiological substrate n-myc downstream regulated 1 (NDRG1). Given the very modest 
reduction in Akt activity upon loss of mTORC2, as discussed above, is Akt a major mTORC2 
effector?  Studies in both yeast and worms suggest that SGK is the main TORC2 effector in 
these organisms. Whether SGK1 is also the most important physiological substrate of 
TORC2 in mammals is not clear.  SGK1-SGK3 double knockout (DKO) mice have a mild 
phenotype, including a defect in renal function that does not affect embryonic development 
(Grahammer et al., 2006).  In contrast, Akt1-Akt2 DKO mice and Akt1-Akt3 DKO mice are 
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impaired in development, and the latter display a phenotype similar to that of rictor knockout 
mice (Guertin et al., 2006; Peng et al., 2003; Shiota et al., 2006; Yang et al., 2005).  
Furthermore, loss of either rictor (Guertin et al., 2009) or Akt1 (Chen et al., 2006) suppresses 
the development of prostate neoplasia in Pten (phosphatase and tensin homolg) deficient 
mice.  These findings are similar to those in D. melanogaster where tissue hyperplasia and 
increased Akt activity induced by Pten loss are reduced upon loss of rictor.  Curiously, loss of 
rictor in the Pten prostate cancer mouse model reduces Akt phosphorylation at both Thr308 
and Ser473.  Overall, Akt still seems to be an important mTORC2 effector, at least upon 
enhanced signalling through the PI3K pathway. 
 
While the processes downstream of TORC2 are coming into focus, knowledge on TORC2’s 
upstream regulators is almost completely lacking.  In yeast, absolutely nothing is known 
about extracellular or intracellular signals controlling TORC2.  In mammalian cells, mTORC2 
phosphorylates Akt upon serum stimulation, in particular growth factors such as insulin and 
insulin-like growth factor 1 (IGF1), suggesting that mTORC2 is regulated by the PI3K 
pathway (Frias et al., 2006; Ikenoue et al., 2008; Jacinto et al., 2006; Yang et al., 2006).  
This observation alone does not indicate that intrinsic mTORC2 kinase activity is stimulated 
by the PI3K pathway.  Activation of PI3K leads to the production of phosphatidylinositol 3,4,5 
trisphosphate (PIP3) and recruitment of Akt to the plasma membrane where it is 
phosphorylated by PDK1 and a possibly constitutively active, membrane-bound mTORC2.  
Thus, mTORC2 could be constitutively active and its regulated phosphorylation of Akt is 
controlled at the level of Akt localization.  However, arguing against this possibility and in 
favor of a model in which the PI3K pathway stimulates intrinsic mTORC2 kinase activity are 
the observations that mTORC2-dependent mTOR autophosphorylation at Ser2481 (Copp et 
al., 2009) and in vitro mTORC2 activity are stimulated by growth factors (Frias et al., 2006; 
Yang et al., 2006).  Furthermore, mTORC2 appears to phosphorylate SGK1 in response to 
growth factors even though SGK1 lacks a PH domain and is activated independently of 
membrane recruitment.  Taken together, these latter findings suggest that growth factors, via 
the PI3K pathway, stimulate intrinsic mTORC2 kinase activity.   
 How might growth factors activate mTORC2 kinase activity?  Despite several 
indications that growth factors stimulate mTORC2 activity, it remains a mystery how the 
growth factor signal is relayed within the cell to activate mTORC2.  A recent report suggests 
that growth factors could signal to mTORC2 via the TSC1-TSC2 complex (a complex of the 
two tuberous sclerosis complex proteins 1 and 2).  Huang et al. (Huang et al., 2008) have 
proposed that the TSC1-TSC2 complex, a GTPase activating protein (GAP) that lies 
upstream of and negatively regulates mTORC1, also regulates mTORC2 function by binding 
directly to mTORC2.  In contrast to the negative regulation of mTORC1 by TSC1-TSC2, 
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TSC1-TSC2 is proposed to positively regulate mTORC2 activity in a GAP-independent 
manner.  The GTPase Rheb, which lies directly downstream of TSC1-TSC2 and activates 
mTORC1 (Manning and Cantley, 2003), does not appear to lie upstream of mTORC2.  The 
observation that TSC1-TSC2 GAP-activity is not required for mTORC2 activation suggests 
that the mechanism is not via mTORC1 and the negative feedback loop, which is a hallmark 
of activated mTORC1 signaling.  The mTORC1 substrate S6K directly phosphorylates insulin 
receptor substrate (IRS) thereby promoting degradation of IRS (Tremblay et al., 2007).  As a 
consequence, further Akt signaling by insulin is attenuated and cells are in an insulin-
resistant state.  Indeed, Huang et al. argue that TSC-mediated activation of mTORC2 is not 
via the negative feedback loop.  The way in which TSC1-TSC2 binding to mTORC2 
regulates mTORC2 activity as well as potential GAP-independent activities for TSC1-TSC2 
remain poorly understood. 
 Is mTORC2 found at the plasma membrane and is mTORC2 localization regulated?  
In the Pten prostate cancer mouse model, where PI3K signaling is increased, rictor and 
Ser473-phosphorylated Akt are enriched at the plasma membrane.  Furthermore, Partovian 
et al. (Partovian et al., 2008) demonstrated that a Syndecan-4 deficiency reduces mTORC2 
localization to detergent-insoluble membrane fractions (rafts) in endothelial cells.  
Interestingly, Syndecan-4, which is a single-pass transmembrane proteoglycan, recruits 
PKCα to the plasma membrane and thereby regulated PKCα activity; this, in turn, is required 
for proper mTORC2 localization to the rafts and subsequent Akt activation.  However, the 
mechanism by which PKCα regulates mTORC2 recruitment is not known, and is further 
complicated by the fact that PKCα is known to be a downstream target of mTORC2. 
  Although we have some insights into how mTORC2 might be regulated, it will be a 
major breakthrough to identify upstream regulators of the TORC2 signaling branch, in both 
yeast and mammals. 
 
 
Concluding remarks and future perspectives 
We have summarized and highlighted the major recent findings on TORC2 in various 
organisms.  The sum of all studies clearly shows conserved functions of TORC2 across 
organisms (Figure I-1).  In plants and algae, many components of the TOR signaling 
pathway have been elucidated and Arabidopsis Thaliana TOR (AtTOR) is important in the 
control of plant growth (Anderson et al., 2005; Deprost et al., 2007; Diaz-Troya et al., 2008; 
Mahfouz et al., 2006).  However, no rictor or Sin1 homologue has been identified in A. 
thaliana or the green alga Chlamydomonas reinhardtii questioning the existence of TORC2 in 
photosynthetic organisms.  Interestingly, TORC2 was recently identified in the protozoan 
parasite Trypanosoma brucei, which causes sleeping sickness in humans (Barquilla et al., 
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2008).  In contrast to other eukaryotes, rapamycin treatment of T. brucei inhibits cell growth 
by exclusively preventing TORC2 assembly, without affecting TORC1. 
 
TORC2, together with its sibling complex TORC1, is the main kinase that phosphorylates 
and thereby regulates the activity of several AGC kinases.  TORC2 also regulates actin 
cytoskeletal organization in most systems studied.  However, it remains unclear how TORC2 
specifically regulates this process in the context of diverse physiological processes that 
involve motility, such as embryogenesis, inflammation, metastasis, or wound healing.   
Several studies have shown that a full body knockout of any mTORC2 component is 
embryonic lethal.  As a next step, it would be highly interesting to determine how mTORC2 in 
individual organs influences whole body growth and metabolism.  Conditional knockout 
studies of the mTORC2-specific component rictor in skeletal muscle display minimal 
phenotypes (Bentzinger et al., 2008; Kumar et al., 2008), suggesting that the role of 
mTORC2 in muscle is less important.  Loss of rictor in adipose tissue, however, results in a 
more dramatic phenotype.  Adipose mTORC2 negatively controls whole-body growth and 
also influences glucose metabolism by influencing IGF1 and insulin levels, respectively (work 
of this thesis: Cybulski et al., 2009). 
 
Does mTORC2 have a role in diseases such as cancer or metabolic disorders?  Guertin et 
al. (Guertin et al., 2009) made the interesting observation that mTORC2 is important for the 
development of prostate cancer induced by Pten loss, but is not important for non-cancerous 
prostate epithelial cells.  Moreover, as conditional knockout studies show a role for mTORC2 
in regulating glucose metabolism, mTORC2 could play a role in the development of type 2 
diabetes ( work of this thesis: Cybulski et al., 2009; Kumar et al., 2008).  The involvement of 
mTORC2 in diseases is only starting to be considered.  Future studies might reveal the need 
for drugs that specifically inhibit mTORC2, such as rapamycin for mTORC1. 
 
 
mTOR associated diseases 
 
Dysregulated mTOR signaling is often linked to tumor formation (Guertin and Sabatini, 
2007).  mTOR itself is not mutated in tumors or cancers, but many upstream regulators and 
downstream effectors that are functionally linked to the mTOR signaling pathway are well-
known proto-oncogenes or tumor suppressors.  The most evident link between aberrant 
mTOR signaling and tumor formation is found in patients with tuberous sclerosis complex, a 
disease characterized by hamartomas (begin tumors) caused by inactivating mutations of the 
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tumor suppressors TSC1 and TSC2 (Inoki et al., 2005).  Hamartomas are also found in 
patients with Peutz-Jeghers syndrome (PJS).  In PJS mTOR signaling is increased due to a 
loss of function mutation in the negative upstream regulator LKB1.  Further proto-oncogenes 
that are commonly activated in cancers and that result in increased mTOR signaling are 
PI3K, Akt/PKB, Rheb and S6K1, while inactivating mutations in the tumor suppressors PTEN 
and 4E-BP1 have the same effect (Wullschleger et al., 2006).  So far, the direct link between 
cancer and mTOR is limited to the mTORC1 signaling branch and rapamycin and its 
derivatives have already been tested in clinical studies for cancer treatment.  However, little 
is known about the role of the mTORC2 signaling branch in cancer.  First indications that 
mTORC2 signaling can be misregulated in cancers come from studies that show that 
mTORC2 is required for the development of prostate cancer caused by PTEN deletion 
(Guertin et al., 2009).  
 
Several studies in mice have shown that mTORC1 signaling in various metabolic tissues 
plays an important role in regulating whole body energy metabolism (Polak and Hall, 2009) 
and dysregulation of mTOR signaling is associated with metabolic disorders such as obesity 
and diabetes.  As described above, constitutive activated mTORC1 signaling inhibits IRS via 
the negative feedback loop from mTOR-S6K resulting in a strong inhibition of the insulin-
mediated PI3K pathway.  As a consequence, cells become desensitized to insulin, causing 
insulin resistance.   
Far less is known about mTORC2 and its role in regulating whole body energy 
metabolism.  First knockout studies revealed that, at least in muscle, loss of mTORC2 results 
in little-to-no phenotype.  Muscle-specific rictor knockout mice are slightly glucose tolerant 
but don’t show any further metabolic abnormalities (Bentzinger et al., 2008; Kumar et al., 
2008). 
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Adipose tissue 
 
It was believed for a long time that the adipose tissue solely functions as a fat storage 
compartment within the body.  However, during the last few years intensive research has 
replaced this view by the notion that adipose tissue also has a central role in lipid and 
glucose metabolism and functions as an endocrine organ.  Adipose tissue is an important 
player in the regulation of energy homeostasis (Figure I-4).   
 
Adipose tissue is considered to be a vital 
organ, is unique to vertebrates and is 
found in most mammals, birds, reptiles 
and amphibians.  It is mainly composed 
of the fat-storing adipocytes, which can 
determine up to 85% of the white adipose 
tissue mass, but adipose tissue also 
comprises other cell types, such as 
macrophages, fibroblasts, preadipoyctes, 
nerve and endothelial cells.  Adipocytes 
have a great capacity to store fat and can 
expand to a size larger than most other 
cell types.  The fat is stored within a 
single large lipid droplet that can 
represent approximately 90% of the cell 
volume of an adipocyte (Haugen and 
Drevon, 2007).  In addition to white 
adipose tissue, also brown adipose tissue exists.  Brown adipocytes store fat in multiple lipid 
droplets and they contain a large number of mitochondria, which give them their brown 
appearance.  In contrast to the fat storage function of white adipose tissue, brown adipose 
tissue has a primary function in heat generation and adaptive thermogenesis by means of 
uncoupling of the proton gradient from ATP production.  Due to this function brown adipose 
tissue has an important role in the thermoregulation of small, hibernating rodents.  In 
humans, brown adipose tissue is found in newborns but is largely replaced by white adipose 
tissue in adults (Cannon and Nedergaard, 2004). 
 
In the following part the role of white adipose tissue in fat storage, fat release, its function as 
an endocrine organ, as well as associated diseases will be described in more detail.  
 
       Figure I-4: Interplay of metabolic tissues.   
       Adapted from Shi and Burn, 2004. 
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Fat storage and release 
 
The primary role of adipose tissue, in particular of the adipocyte cell, is to store energy in the 
form of triacylglycerol (TAG) during times when input exceeds expenditure and to break 
down this stored lipid into free fatty acids (FFA) when energy is required (Haugen and 
Drevon, 2007).  TAGs are lipid molecules composed of three fatty acids attached to a 
glycerol backbone.  Fatty acids can be saturated or unsaturated.  The main source of FFAs 
comes from the diet, but upon shortage, FFAs can also be synthesized by the body from 
glucose in a process called de novo lipogenesis.  In the diet, fat is mainly stored as TAGs, 
and many fats that originate from animals are mainly composed of saturated fatty acids, 
whereas vegetable-derived fats often contain a high percentage of unsaturated fatty acids. 
 
Upon food intake, dietary fats are first digested in the stomach and upper small intestine 
through the action of stomach acids, bile salts, and digestive enzymes, such as lipases.  In 
the intestinal cells, the absorbed fat is re-assembled into TAGs and packaged together with 
cholesterol, fat-soluble vitamins and carrier lipoproteins into small particles called 
chylomicrons that are then secreted into the blood stream.  Except for the liver, most organs 
are able to extract the lipids from the chylomicrons with the help of lipoprotein lipases, which 
are secreted by the individual organs and are found in the capillaries of mainly heart, skeletal 
muscle and adipose tissue, but also other non-liver organs.  Lipoprotein lipases break the 
TAGs down into free fatty acids.  While the heart and skeletal muscle metabolize the fatty 
acids for energy production, the adipose tissue stores the fatty acids by forming new TAGs.  
Once the chylomicrons are depleted of TAGs and remain loaded with cholesterol, they are 
known as chylomicron remnants that are taken up by the liver (Shi and Burn, 2004).   
Between meals, the liver can also synthesize TAGs from glucose, which are then 
distributed to the body in the form of very low density lipoproteins (VLDL).  VLDLs provide 
fatty acids mainly to the heart and skeletal muscle for oxidation and as more and more TAGs 
are removed, the composition of the VLDL changes and it becomes an intermediate-density 
lipoprotein (IDL).  Further loss of TAGs results in smaller and denser particles called low 
density lipoproteins (LDL), that are then enriched in cholesterol.  LDLs provide cholesterol to 
peripheral tissues.  LDL is often referred to as the ‘bad’ cholesterol fraction, since an excess 
of LDL in the blood stream is a major cause of atherosclerosis.  The ‘good’ cholesterol 
fraction is known as high density lipoprotein (HDL).  HDL is assembled in the blood and 
transports excess cholesterol away from or out of tissues back to the liver for eventual 
disposal.   
As mentioned before, the adipose tissue stores dietary fat as TAG.  FFAs that are 
released from lipoproteins (mainly chylomicrons) by lipoprotein lipase enter the adipocytes 
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through both passive diffusion and active transport.  FFAs are toxic to cells, so once inside 
the cell they are transported via fatty acid-binding proteins and converted to acyl coenzyme A 
(acyl-CoA).  This activated form of FFA can then be either oxidized by mitochondria for 
energy generation (more common in other cells), or be transported to the endoplasmic 
reticulum for esterification with glycerol 3-phosphate that is generated by glucose 
metabolism.  The formation of TAGs requires several enzymatic steps and once synthesized 
the TAGs are stored away into lipid droplets. 
 
During fasting or exercise, fatty acids and glycerol are released from the adipose tissue into 
the blood stream in order to supply peripheral tissues with sufficient energy.  The process of 
lipid mobilization by releasing FFAs is called lipolysis.  In the fed state, lipolysis is inhibited by 
insulin, while in the starved state epinephrine and other lipolytic hormones promote the 
breakdown of stored TAGs.  At least three adipocyte lipases are required to release the three 
fatty acids bound to one glycerol backbone.  Adipose TAG lipase (ATGL) removes the first 
fatty acid, followed by hormone-sensitive lipase (HSL) that degrades the diacylglycerols into 
monoacylglycerols.  The last step requires monoglyceride lipase.   
Activation of lypolysis through lipolytic hormones causes an increase in intracellular cyclic 
AMP (cAMP) levels and activation of cAMP-dependent protein kinase A (PKA).  Activated 
PKA phosphorylates and activates HSL, which regulates the rate-limiting step of lipolysis.  
PKA also phosphorylates perilipin, a lipid-droplet-coating protein, that when phosphorylated, 
facilitates access of HSL to the lipid droplet, and hence lipolysis.  Once released into the 
blood, FFAs are transported in an albumin-bound form to different tissues that can oxidize 
them, mainly liver, heart, kidney and muscle (Shi and Burn, 2004). 
 
 
Endocrine functions 
 
Adipose tissue has long been believed to be solely a fat storage depot, but it is now clear 
that adipose tissue is a complex and highly active metabolic and endocrine organ.  It has the 
capacity to actively communicate by sending and receiving different types of signals.  
Adipose tissue expresses many receptors that allow it to respond to endocrine and autocrine 
signals, such as insulin, glucagon, catecholamines, insulin like growth factor 1 (IGF1) and 
many others.  On the other hand, it also secretes a variety of factors, including metabolites 
and proteins that derive from both adipocyte and nonadipocyte fractions.  These 
metabolically active adipose-derived factors are commonly known as “adipokines” and they 
affect whole body energy metabolism and the function of many organs and tissues including 
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muscle, liver, vasculature, and brain.  Adipokines act in an autocrine, paracrine and/or 
endocrine manner and are involved in glucose and lipid metabolism, inflammation, 
coagulation, blood pressure and feeding behavior (Kershaw and Flier, 2004; Wang et al., 
2008). 
The two best-characterized and most studied adipokines are leptin and adiponectin.  
Leptin is a small protein secreted from adipocytes and its serum levels correlate with adipose 
tissue mass as well as the nutritional status (Friedman, 2009).  However, leptin levels are not 
directly influenced by short-term nutritional status (food intake) but rather reflect the long-
term nutritional status.  Leptin acts through the sympathetic nervous system to negatively 
regulate appetite and food intake.  Its binding to the leptin receptor in the hypothalamus 
results in the reduction of neuropeptide-Y (NPY) and agouti regulated protein (AgRP) activity, 
two orexigenic neuropeptides, while increasing the activity of the anorexigenic neuropeptides 
pro-opiomelanocortin (POMC) and cocaine- and amphetamine related protein (CART).  
Leptin was discovered in 1994 as the product of the obese (ob) gene.  Mice with a mutation 
in the ob gene are extremely obese due to the lack of functional leptin, resulting in a reduced 
feedback signal to stop eating.  Besides its central role in regulating food intake and energy 
expenditure, leptin also influences lipid metabolism by increasing hepatic lipid oxidation and 
lipolysis in skeletal muscle and adipocytes (Hajer et al., 2008). 
Adiponectin is another protein hormone that is produced exclusively by adipocytes and is 
regarded as an insulin sensitizer that plays an important role in the development of insulin 
resistance.  In contrast to most other adipokines, serum adiponectin levels negatively 
correlate with adipose tissue mass (Garaulet et al., 2007).  Adiponectin improves insulin 
sensitivity by reducing hepatic glucose production and enhancing insulin action in the liver 
and skeletal muscle. 
Many additional adipokines and their associated role in regulating whole body energy 
metabolism have been identified (Kershaw and Flier, 2004; Wang et al., 2008).  The 
following table gives an overview of the functional groups of adipokines and the major factors 
involved: 
Functional category Factors 
Lipid metabolism Cholesteryl ester transfer protein (CETP), Lipoportein lipase (LPL), 
Retinol binding protein 4, Apolipoprotein E, Steroid hormones 
Glucose metabolism and 
insulin resistance 
Adiponectin, Resistin, Visfatin, Omentin, Vaspin, Leptin, TNFα 
Food intake Leptin 
Inflammation Tumor necrosis factor α (TNFα), Interleukin-6 (IL-6), Adiponectin, 
Resistin, C-reactive protein (CRP), Adipsin 
Vasculature Angiotensin, Vascular endothelial growth factor (VEGF), 
Adrenomedullin, Plasminogen activator inhibitor-1 (PAI-1) 
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Adipose tissue associated diseases 
 
Body fat has the very important function of storing fatty acids for times of low energy 
availability.  However, the right amount of body fat is very important as too much or too little 
fat are a serious health risk. 
Obesity, an excess of body fat results from an imbalance of caloric intake and energy 
expenditure, but also genetic factors can influence the progression of obesity.  Obesity is 
strongly associated with many diseases, in particular diabetes and cardiovascular diseases 
(Hajer et al., 2008).  As mentioned before, adipose tissue has an important function as an 
endocrine organ to control whole body energy homeostasis and obesity is often associated 
with marked changes in the secretory function of the adipose tissue that promotes the 
development of diseases.  
Obesity-linked type 2 diabetes is due to a combination of insulin resistance and 
dysfunction of the insulin-secreting pancreatic β-cells (Guilherme et al., 2008; Lingohr et al., 
2002).  Insulin resistance results from an impaired insulin responsiveness of skeletal muscle 
resulting in diminished glucose uptake.  In a first step, normal glucose levels can be 
maintained by increased insulin production/secretion by pancreatic β-cells.  However, when 
the pancreatic β-cells fail to secrete enough insulin to compensate for insulin resistance, 
blood glucose levels rise and diabetes will ensue.  Several adipose-derived factors, such as 
adiponectin, TNFα, leptin, IL6 and FFAs, are known to affect insulin sensitivity of peripheral 
tissues, and they furthermore have effects in the pancreas leading to β-cell failure (Hajer et 
al., 2008). 
Obesity is also a major risk factor for hypertension and cardiovascular diseases, in 
particular coronary heart disease (Bays, 2009).  High blood glucose levels (resulting from 
type 2 diabetes), elevated blood pressure, elevated TAGs, low plasma HDL and high plasma 
LDL are associated with obesity and are all known to increase the risk for coronary heart 
disease. 
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Cell migration  
 
Cell migration is involved in many physiological and pathophysiological processes including 
embryogenesis, angiogenesis, nerve growth, tissue repair, inflammation, invasion or 
metastasis (Franz et al., 2002), and normally requires the orchestrated movement of cells in 
a particular direction to a specific location. 
Cell migration is a very dynamic and highly coordinated process, which involves rapid 
changes in the dynamics of actin filaments, together with the formation and disassembly of 
cell adhesion sites.  The migration process can be divided into five different steps (Ridley et 
al., 2003).  Directed cell movement is initiated by protrusion of the leading edge and 
formation of new actin filaments followed by adhesion to the matrix.  The third step in the 
migratory process is cell-body contraction resulting from forces generated through 
actomyosin interactions.  The next event involves the release of cell contacts at the rear of 
the cell and the cycle ends with the recycling of membrane receptors from the rear to the 
front, which relies mainly on protein trafficking.  Each step of the cycle requires a highly 
coordinated restructuring of the actin cytoskeleton.  The protrusive structures at the leading 
edge of a motile cell are called lamellipodia and filopodia.  A lamellipodium is a thin, flat and 
sheet-like protrusion that is filled with a branched network of actin filaments, while filopodia 
are thin, spike-like structures that are filled with tight parallel bundles of filamentous actin.  
The main regulators of the actin cytoskeleton, and hence important regulators of direct cell 
migration, are the Rho GTPases (Hall, 1998; Heasman and Ridley, 2008). 
 
Rho GTPases belong to the family of small GTPases and are mainly known for their role in 
controlling actin cytoskeletal assembly and contraction, but RhoGTPases are also involved in 
other important processes including regulation of cell polarity, microtubule dynamics, 
vesicular transport pathways and gene transcription (Jaffe and Hall, 2005).  RhoGTPases 
function as molecular switches that cycle between an active GTP-bound form and an inactive 
GDP-bound form.  The cycling of Rho GTPases between these two states is regulated by 
three sets of proteins. (1) Guanine nucleotide exchange factors (GEFs) facilitate the 
exchange process, (2) GTPase-activating proteins (GAPs) facilitate inactivation of GTP-
bound Rho by increasing GTPase activity, and (3) guanine nucleotide dissociation inhibitors 
(GDI) prevent dissociation of GDP and thereby prevent activation.  Upon activation, Rho 
proteins interact with and activate downstream effector proteins to stimulate a variety of 
processes. 
Mammalian RhoGTPases comprise a family of 20 members, but the most highly 
conserved and most extensively studied Rho GTPases are RhoA, Rac1 and Cdc42.  RhoA is 
implicated in the formation of stress fibers and focal adhesions, Rac1 promotes 
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lamellipodium formation and Cdc42 functions in the formation of filopodia (Ladwein and 
Rottner, 2008; Mattila and Lappalainen, 2008). 
Fibroblasts are commonly used to study the basic mechanisms of cell migration 
because they contain the fundamental machinery for cell migration. 
 
 
 
Aims of the Thesis 
 
Full body knockout of any mTORC2-component in mice results in embryonic lethality 
emphasizing the importance of this complex at least in embryogenesis.  However, very little 
is known about mTORC2 function in individual tissues and its role in whole body metabolism.  
Furthermore, compared to the mTORC1 signaling branch, the mTORC2 signaling branch is 
less characterized and little is known about its upstream regulators and downstream 
functions.  Therefore, the aim of this thesis was to gain new insights into the in vivo and in 
vitro functions of mTORC2. 
The first part focuses on the in vivo function of mTORC2 and describes the 
phenotypic characterization of adipose-specific knockout mice of the mTORC2-specific 
component rictor.  mTORC2 signaling is activated upon insulin stimulation and adipose 
tissue is one of the most insulin-sensitive tissues in the body strongly suggesting a role for 
mTORC2 in this tissue. 
The second part of this thesis focuses on the in vitro function of mTORC2 and 
analyses its role in cell migration.  Using an inducible knockout mouse embryonic fibroblast 
(MEF) cell line for rictor, the effects of loss of mTORC2 were investigated.   
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Abstract 
 
Mammalian Target Of Rapamycin (mTOR), a highly conserved protein kinase that controls 
cell growth and metabolism in response to nutrients and growth factors, is found in two 
structurally and functionally distinct multiprotein complexes termed mTOR complex 1 
(mTORC1) and mTORC2.  mTORC2, which consists of rictor, mSIN1, mLST8, and mTOR, is 
activated by insulin/IGF1 and phosphorylates Ser473 in the hydrophobic motif of Akt/PKB.  
While the role of mTOR in single cells is relatively well characterized, the role of mTOR 
signaling in specific tissues and how this may contribute to overall body growth are poorly 
understood.  To examine the role of mTORC2 in an individual tissue, we generated adipose-
specific rictor knockout mice (rictorad-/-).  rictorad-/- mice are increased in body size due to an 
increase in size of non-adipose organs including heart, kidney, spleen, and bone.  
Furthermore, rictorad-/- mice have a disproportionately enlarged pancreas and are 
hyperinsulinemic, but glucose tolerant, and display elevated levels of insulin-like growth 
factor 1 (IGF1) and IGF1 binding protein 3 (IGFBP3).  These effects are observed in mice on 
either a high fat or a normal diet, but are generally more pronounced in mice on a high fat 
diet (HFD).  Our findings suggest that adipose tissue, in particular mTORC2 in adipose 
tissue, plays an unexpectedly central role in controlling whole body growth.  
 
 
Introduction 
 
Mammalian Target Of Rapamycin (mTOR), a highly conserved protein kinase that controls 
cell growth and metabolism in response to nutrients and growth factors, is found in two 
structurally and functionally distinct multiprotein complexes termed mTOR complex 1 
(mTORC1) and mTORC2 (Wullschleger et al., 2006).  mTORC1 contains raptor, mLST8, 
PRAS40 and mTOR, and is sensitive to the immunosuppressant and anti-cancer drug 
rapamycin (Hara et al., 2002; Kim et al., 2002; Loewith et al., 2002; Vander Haar et al., 
2007).  mTORC2 consists of rictor, mSIN1, mLST8 and mTOR, and is insensitive to 
rapamycin although long-term rapamycin treatment can indirectly inhibit mTORC2 in some 
cell types (Jacinto et al., 2006; Jacinto et al., 2004; Sarbassov et al., 2004; Sarbassov et al., 
2006; Yang et al., 2006).  The best-characterized substrates of mTOR are S6K and 4E-BP 
via which mTORC1 controls translation, and Akt/PKB via which mTORC2 may control cell 
survival and possibly other processes (Hresko and Mueckler, 2005; Polak and Hall, 2009; 
Sarbassov et al., 2005).  mTORC2 also phosphorylates and activates SGK1, and 
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phosphorylates and stabilizes PKCα (Facchinetti et al., 2008; Garcia-Martinez and Alessi, 
2008; Ikenoue et al., 2008; Sarbassov et al., 2004).  As mTORC1 can be pharmacologically 
inhibited with rapamycin, it is relatively well characterized and has been implicated in various 
disorders including cancer, cardiovascular disease, obesity and diabetes (Wullschleger et al., 
2006).  In contrast, as there is no specific inhibitor of mTORC2, mTORC2 signaling is less 
well characterized and its physiological role is unclear.  Knockout studies have underscored 
the importance of both complexes as full body deletion of any component of either mTOR 
complex results in embryonic lethality (Guertin et al., 2006; Jacinto et al., 2006; Shiota et al., 
2006; Yang et al., 2006).  rictor-deficient embryos fail to develop beyond day E10.5 and 
arrest as slightly smaller and developmentally delayed embryos compared to littermate 
controls (Guertin et al., 2006; Shiota et al., 2006). 
While the general role of mTOR in single cells is relatively well characterized, the role 
of mTOR signaling in specific tissues and how this may contribute to overall body growth and 
whole body metabolism are poorly understood (Polak and Hall, 2009).  Adipose-specific 
raptor knockout mice are resistant to diet-induced obesity and have improved glucose 
metabolism (Polak et al., 2008).  Conditional knockout of raptor in skeletal muscle results in 
slight glucose intolerance, muscle dystrophy, and death by the age of 6 months (Bentzinger 
et al., 2008).  Knockout of rictor specifically in skeletal muscle results in little-to-no phenotype 
and thus provided little insight on the physiological role of mTORC2 at least in muscle 
(Bentzinger et al., 2008; Kumar et al., 2008). 
Adipose tissue is a fat storage depot and an endocrine organ that controls energy 
metabolism, appetite and fertility in response to nutrients and insulin (Haugen and Drevon, 
2007; Shi and Burn, 2004).  Interestingly, the equivalent tissue in Drosophila, the fat body, 
controls full body growth in response to nutrients.  Colombani et al (Colombani et al., 2003) 
have demonstrated that down regulation of TOR signaling, most likely mTORC1, specifically 
in the fat body results in a reduction in overall body size.  Excess adipose tissue (obesity) 
leads to many metabolic disorders including type 2 diabetes, cardiovascular diseases and 
cancer.  Given the central role of mTOR as a nutrient sensor and the increasing prevalence 
of obesity, it is important to understand the role of adipose mTOR in controlling whole body 
growth and metabolism.  In this study, we examined the role of mTORC2 in adipose tissue.  
To circumvent the embryonic lethality caused by full body ablation of any component of 
mTORC2, we used the Cre/LoxP system to knock out rictor specifically in adipose tissue.  
Strikingly, rictorad-/- mice are enlarged due to an increase in lean tissue mass resulting from 
elevated levels of IGF1.  Furthermore, the knockout mice are hyperinsulinemic yet glucose 
tolerant.  These results suggest the existence of an mTORC2-dependent adipose to 
liver/pancreas signaling axis that controls full body growth and metabolism.  
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Results 
 
Generation and confirmation of adipose-specific rictor knockout mice.   
To delete rictor in adipose tissue, we generated mice in which exons four and five of the 
rictor gene were flanked by loxP sites (rictorfl/fl).  The rictorfl/fl mice were crossed with mice 
expressing cre recombinase under control of the adipose-specific, fabp4/aP2 gene promoter 
(He et al., 2003) (Fig. II-1A).  Adipose-specific rictor knockout mice (rictorad-/-) lacked rictor 
protein in adipose tissue but not in liver, heart, kidney, spleen, brain or macrophages (Fig. II-
1B and II-S1), indicating that rictor was indeed deleted specifically in adipocytes.   Adipose 
tissue of rictorad-/- mice exhibited reduced Akt Ser473 phosphorylation and reduced PKCα 
levels, indicating that mTORC2 signaling was defective (Fig. II-1B).  As expected, Akt Thr308 
phosphorylation and phosphorylation of the Akt substrate GSK3 were not affected in adipose 
tissue.   
  
rictorad-/- mice are enlarged due to an increase in lean mass.   
Body weight of rictorad-/- and control wild type littermates (rictorfl/fl) was monitored during a 10 
week time course in mice 8 to 18 weeks of age.  At 8 weeks of age, knockout and control 
mice were of similar weight.  On a normal diet (chow), rictorad-/- mice gained weight at a 
slightly higher rate than control mice such that they were 4% heavier at the end of the time 
course (Fig. II-1C).  The increased body weight of rictorad-/- mice compared to control mice 
was more pronounced on a HFD (Fig. II-1D).  After ten weeks on a HFD (started at 8 weeks 
of age), the rictorad-/- mice were 17% heavier than control rictorfl/fl mice, but were already 
significantly heavier after only 5-6 weeks on the HFD.  Body length of the rictorad-/- mice was 
also increased (Fig. II-1E), suggesting that the increase in weight was due to an overall 
increase in body size rather than an increase only in fat mass.  Indeed, whole body dexa 
scan analysis of mice after 6 weeks on a HFD revealed an increase specifically in lean tissue 
mass (Fig. II-2A); no difference was observed in the total amount of fat mass after 6 weeks 
on a HFD (Fig. II-2B).   
To investigate further the increase specifically in lean tissue mass, individual organs 
of rictorad-/- and rictorfl/fl mice, fed either a chow or high fat diet for 10 weeks, were excised 
and weighed (Fig, II-2C-J).  On a chow diet, the heart, kidneys, spleen, and pancreas were 
40%, 28%, 38%, and 41% heavier, respectively, in rictorad-/- mice compared to rictorfl/fl control 
mice.  On a HFD, the heart, kidneys, spleen and pancreas were 40%, 47%, 62%, and 129% 
heavier, respectively, in rictorad-/- mice (Fig. II-2C-F).  Interestingly, the pancreas was heavier 
in the rictorad-/- mice on both diets but was disproportionately heavier (129%) on the HFD, 
compared to other organs (Fig. II-2F).  The liver was also heavier (75%) in rictorad-/- mice, but 
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only on the HFD (Fig. II-2G).  Furthermore, as revealed by whole body dexa scan analysis, 
rictorad-/- mice exhibited a 15% increase in bone mineral content with no change in bone 
mineral density, indicating that overall bone size was also increased (Fig. II-2H).  Thus, all 
lean tissues examined were enlarged as a result of an mTORC2 deficiency in adipose tissue. 
After ten weeks on a HFD, the inguinal fat pad was not significantly increased in 
rictorad-/- mice compared to control rictorfl/fl mice (Fig. II-2I), although the epididymal fat pad 
was increased 30% (Fig. II-2J).  This is consistent with the dexa scan analysis described 
above which detected no increase in overall fat mass after six weeks on a HFD.  Thus, 
rictorad-/- mice are larger than control mice due to an increase mainly, if not exclusively, in 
lean tissue mass.  Surprisingly, this effect was particularly evident in mice on a HFD.  
Furthermore, given the increase in lean mass with little-to-no increase in overall fat mass, 
rictorad-/- mice are leaner than control mice.  This leanness could account for the relatively 
mild increase in full body weight (17%) compared to the observed increases in weights of 
individual organs. 
 
rictorad-/- mice exhibit normal WAT morphology and have increased liver steatosis.   
To investigate further the effect of rictorad-/- on adipose tissue, we performed histology on the 
epididymal fat pad.  The epididymal fat pads from rictorad-/- and control rictorfl/fl mice were 
indistinguishable with regard to fat cell size and morphology (Fig. II-3A).  We also examined 
histological sections of the liver, a secondary fat storage organ.  Hepatic cells from HFD-fed 
rictorad-/- mice contained particularly enlarged lipid droplets, indicative of more advanced 
steatosis (Fig. II-3B).  Quantification of liver triglycerides confirmed the increased fat 
accumulation in the liver of rictorad-/- mice compared to control rictorfl/fl mice (Fig. II-3C).  The 
amount of glycogen in the liver was not changed in rictorad-/- mice compared to control mice 
(Fig. II-S2).  Thus, the increase in hepatic fat accumulation likely accounts for the particularly 
enhanced size (75% increase) of the liver in HFD-fed rictorad-/- mice, as described above. 
 
rictorad-/- mice have altered levels of cholesterol and adiponectin.   
To characterize further the phenotype of rictorad-/- mice, we examined several blood 
metabolites and hormones that could be affected upon altered adipose function.  Free fatty 
acids and triglyceride levels were unchanged in rictorad-/- mice compared to rictorfl/fl mice. 
Cholesterol levels were increased in rictorad-/- mice, but only on a chow diet.  Serum leptin 
and IL-6 were also unchanged, but serum levels of adiponectin were decreased 
approximately 30% in rictorad-/- mice, on either a chow or high fat diet (Table II-1). 
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rictorad-/- mice are hyperinsulinemic but glucose tolerant.   
To assess the role of adipose mTORC2 in whole body glucose metabolism, we first 
examined blood glucose and insulin levels.  On a chow or high fat diet, blood glucose levels 
were similar or slightly lower in both fasted (overnight) and fed rictorad-/- mice compared to 
control rictorfl/fl mice (Fig. II-4A,B).  However, insulin levels were significantly increased in 
fasted or fed rictorad-/- mice compared to control mice, on a chow or high fat diet (Fig. II-
4C,D).  To further investigate the effect of mTORC2-deficient adipose tissue on insulin levels, 
we performed a morphometric analysis on the pancreas.  Consistent with an enlarged 
pancreas, pancreatic islets were at least two-fold larger but otherwise morphologically 
unchanged in rictorad-/- mice compared to control rictorfl/fl mice (Fig. II-4E,F).  Furthermore, the 
increase in size of the islets correlated with an increase in total weight of β cells (Fig. II-4G) 
The increase in size of the pancreas and insulin producing islets, even disproportionately 
increased in HFD-fed knockout mice, likely account for the hyperinsulinemia of rictorad-/-mice.  
We next performed a glucose tolerance test on rictorad-/- and control rictorfl/fl mice, on a 
chow or high fat diet.  Hyperinsulinemia, as observed in the rictorad-/- mice, is normally a 
response to insulin resistance and generally correlates with glucose intolerance.  However, 
unexpectedly, the hyperinsulinemic rictorad-/- mice were similarly glucose tolerant (chow diet) 
or even more glucose tolerant (HFD) than rictorfl/fl mice on the corresponding diets (Fig. II-
5A,B).  Furthermore, rictorad-/- mice produced higher levels of blood insulin in response to an 
injected glucose bolus, compared to rictorfl/fl control mice (Fig. II-S3).  Thus, rictorad-/- mice 
remain glucose tolerant under conditions (HFD) where wild type mice are unable to do so.  In 
addition, the hyperinsulinemia of rictorad-/- mice does not correlate with glucose intolerance 
but may rather reflect a primary effect of mTORC2-deficient adipose on the pancreas.  Such 
a primary effect on the pancreas could underlie the disproportionately large size of the 
pancreas in rictorad-/- mice. 
rictorad-/- mice are more glucose tolerant than control mice.  Is this due to increased 
insulin sensitivity, to the observed elevated levels of insulin, or to both?  To distinguish these 
possibilities, we examined the insulin sensitivity of rictorad-/- and rictorfl/fl mice.  rictorad-/- mice 
were slightly insulin resistant compared to the wild type control mice, based on less efficient 
clearance of blood glucose in response to injected insulin (Fig. II-5C).  To investigate further 
this insulin resistance, we examined Akt Thr308 and Ser473 phosphorylation in muscle, 
adipose tissue and liver of insulin-injected rictorad-/- and rictorfl/fl mice.  Mice were injected with 
either saline or insulin and, after 15 minutes, tissues were excised and processed for 
immunoblotting to detect Akt phosphorylation.  Insulin stimulated Thr308 and Ser473 
phosphorylation in both the rictorad-/- and control rictorfl/fl mice in all three tissues, but this 
stimulation was less robust in the rictorad-/- mice (Fig. II-5D).  Thus, rictorad-/- mice are 
modestly insulin resistant, possibly due to reduced levels of the insulin-sensitizer adiponectin 
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(Table II-1).  Furthermore, these results suggest that the glucose tolerance of rictorad-/- mice 
is due to an elevated level of insulin that overcomes a weak insulin resistance. Elevated 
levels of IGF1 (see below) might also contribute to the glucose tolerance of rictorad-/- mice 
(Liao et al., 2006). 
As expected, insulin failed to stimulate mTORC2-dependent Akt Ser473 
phosphorylation in adipose tissue of rictorad-/- mice (Fig. II-5D).  However, insulin stimulated 
Akt Thr308 and GSK3 phosphorylation in adipose tissue of rictorad-/- mice, suggesting that 
mTORC2-deficient adipose tissue remains insulin responsive.  To further investigate the 
insulin responsiveness of mTORC2-deficient adipose tissue, we assayed glucose uptake in 
isolated, insulin-treated adipocytes.  While basal and insulin-stimulated glucose uptake were 
lower in rictor-deficient adipocytes, both rictorad-/- and wild type adipocytes displayed a three-
fold stimulation in response to insulin (Fig. II-5E), confirming that mTORC2-deficient 
adipocytes remain insulin responsive.   
 
rictorad-/- mice have elevated serum IGF1.   
Organismal growth is controlled largely by growth hormone (GH) and IGF1 (Butler and Le 
Roith, 2001; Dupont and Holzenberger, 2003).  GH is produced in the pituitary gland and 
acts by stimulating IGF1 production in the liver. To understand further the increased body 
size of rictorad-/- mice, we measured serum levels of GH and IGF1.  IGF1 serum levels were 
significantly increased in rictorad-/- mice compared to control rictorfl/fl mice, on either a chow 
(21%) or high fat diet (58%) (Fig. II-6A).  The increase in IGF1 levels correlated with an 
increase in IGF1 mRNA levels in the liver, the main IGF1 secreting organ, and in adipose 
tissue (Fig. II-6B).  In parallel, IGF1 binding protein 3 (IGFBP3) serum levels were also 
elevated in rictorad-/- mice, on a chow or high fat diet (26% and 39%, respectively) (Fig. II-6C).  
IGFBP3 is the major IGF1 binding protein that together with acid-labile subunit (ALS) 
stabilizes IGF1 in the serum (Duan and Xu, 2005; Yakar et al., 2005).  In contrast, GH serum 
levels were unchanged (Fig. II-6D), suggesting that elevated levels of IGF1 in the blood were 
not due to altered, GH-mediated signaling from the pituitary gland.  The increased levels of 
IGF1 likely account for the increased body size and furthermore contribute to the glucose 
tolerance of rictorad-/- mice.  
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Discussion 
 
Here we describe the generation and characterization of mice lacking rictor specifically in 
adipose tissue.  rictor is an essential and specific subunit of mTORC2.  The most striking and 
unexpected observation was that rictorad-/- mice are increased in body size due to an 
increase in size of non-adipose tissue.  Furthermore, rictorad-/- mice have elevated levels of 
IGF1 and insulin.  The hyperinsulinemia is likely due to a disproportionately increased 
pancreas and increased β cell mass.  The increase in IGF1 levels is due to a GH-
independent increase in IGF1 expression in adipose tissue and the liver.  Overall, our results 
suggest that mTORC2 in adipose tissue controls an adipose to pancreas/liver signaling axis 
that ultimately controls whole body growth and glucose metabolism.   
How might mTORC2 in adipose control the pancreas and liver?  mTORC2 in adipose 
tissue may positively control expression and/or secretion of a factor(s) that negatively 
regulates these organs.  Alternatively, adipose mTORC2 could negatively control a factor(s) 
that positively regulates the pancreas and/or liver.  In either case, adipose mTORC2 would 
negatively regulate the pancreas and liver such that a knockout of adipose mTORC2 results 
in increased insulin production by the pancreas and increased IGF1 secretion by the liver 
(Fig. II-6E).  The physiological significance of this negative regulation of the pancreas and 
liver by adipose mTORC2 may be related to the fact that mTORC2 is itself stimulated by 
insulin and IGF1 (Wullschleger et al., 2006).  Insulin/IGF1-responsive mTORC2 in adipose 
tissue may be part of a negative feedback endocrine loop acting on the pancreas and liver to 
maintain insulin and IGF1 homeostasis (Fig. II-6E).  Consistent with such a negative 
feedback loop, an adipose-specific knockout of IGF1 receptor results in elevated levels of 
IGF1 and larger mice but unchanged levels of GH (Kloting et al., 2008), similar to the 
adipose-specific mTORC2 knockout described here.  Thus, according to this model, insulin 
and IGF1 activate mTORC2 in adipose tissue and this, in turn, leads to down regulation of 
insulin and IGF1 production in the pancreas and liver, respectively.  It will be of interest to 
determine if disruption of this putative feedback loop between organs plays a role in 
metabolic or growth disorders.  In this context, it is relevant to note that the feedback loop 
appears to be particularly important in response to a high fat diet, as suggested by our 
observation that the growth phenotype of rictorad-/- mice is more pronounced on a high fat 
diet.   
What is the mTORC2-regulated factor(s) that could be signaling from adipose tissue 
to the pancreas and/or liver?  It must be something other than leptin, IL-6, or free fatty acids 
as these factors are unchanged in rictorad-/- mice (Table II-1).  IGF1 expression is increased 
in adipose tissue in rictorad-/- mice, suggesting that IGF1 could be a factor by which adipose 
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mTORC2 signals to other organs.  However, IGF1 produced by adipose tissue would likely 
not be a major factor in signaling to the pancreas and liver because there are few-to-no IGF1 
receptors in the liver, and because the liver is the major producer of circulating IGF1.  The 
secreted factor(s) that signals from adipose to the pancreas and liver remains to be 
determined.  
The downstream effectors of mTORC2 that mediate the effects described here are 
unknown.  mTORC2 controls many AGC family kinases (Jacinto and Lorberg, 2008; Polak 
and Hall, 2009), and we have shown that an mTORC2 deficiency in adipose tissue results in 
reduced Akt Ser473 phosphorylation and reduced levels of PKCα.  It seems unlikely that the 
phenotype described here is due to loss of Akt Ser473 phosphorylation as loss of Akt Ser473 
phosphorylation only mildly affects Akt activity.  PKCα is poorly characterized in adipose 
tissue and it thus remains to be determined whether loss of PKCα plays a significant role.  
Recent findings suggest that the TORC2 substrate and AGC kinase SGK1 plays an 
important role in TORC2 downstream signaling and thus possibly in the phenotype described 
here (Garcia-Martinez and Alessi, 2008; Jones et al., 2009; Soukas et al., 2009).  However, 
SGK1 also remains to be characterized in adipose tissue.  
In summary, our results and the recent results of Kloting et al (Kloting et al., 2008) 
suggest that adipose tissue, and in particular IGF1-mTOR signaling in adipose tissue, plays 
an unexpectedly central role in controlling whole body growth.  This notion is further 
supported by Colombani et al (Colombani et al., 2003) who demonstrated that TOR in the fly 
fat body controls whole body growth, via a hormonal mechanism.  However, mice and flies 
do not appear to be completely analogous, as adipose mTORC1 in mice does not control 
systemic growth positively, as suggested for flies (Polak et al., 2008).  In mice, adipose 
mTORC2 controls systemic growth negatively. 
 
 
Methods 
 
Mice.  LoxP sites were introduced into the intron upstream exon 4 and into the intron 
downstream of exon 5 using a neo cassette flanked with frt sites as a selectable marker (Fig. 
1A).  Expression of Cre recombinase deletes exons 4 and 5 and causes a frameshift in the 
rictor open reading frame.  The vector containing the targeting construct was introduced into 
embryonic stem cells of the129S1/SvlmJ mouse strain and positive ES cells were selected 
by G418 resistance.  Targeted stem cells were injected into blastocysts of C57BL/6J mice to 
obtain chimeric mice.  Injection of ES cells into blastocysts and subsequent generation of 
chimeric mice was performed at the Institut Clinique de la Souris (ICS), Strasbourg, France.  
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After germline transmission, mice were crossed with C57BL/6J mice expressing Flp 
recombinase to remove the neo cassette and subsequently with C57BL/6J Flp deleter mice 
to obtain rictorfl/flmice. The rictorfl/fl mice lack the neo cassette and behave like wildtype.  Mice 
with an adipose-specific deletion of rictor (rictorad-/-) were obtained by crossing rictorfl/fl mice 
with C57BL/6J mice expressing Cre recombinase under the control of the adipocyte-specific 
fabp4/aP2 gene promoter (He et al., 2003) (purchased from JAX Laboratories), which is 
expressed relatively late in adipogenesis (Tontonoz et al., 1994), leading to knockout of rictor 
only in mature adipocytes in neonates.  rictorad-/- mice were born at the expected Mendelian 
ratio.  For all experiments, male mice that had been backcrossed at least 5 times with the 
C57BL/6 strain were used.  Littermates with the lox/lox genotype (rictorfl/fl) were used as 
control group in all experiments and are indistinguishable from wildtype mice. .  All mouse 
experiments described were approved by the Kantonales Veterinaeramt of Kanton Basel-
Stadt. 
 
Metabolic studies.  At 8 weeks of age male mice were either fed a normal chow diet (4.5% 
calories from fat, Kliba Nafag) or put on a high fat diet (60% calories from fat, Harlan 
Research Diets) and monitored for 10 weeks.  Body weight was recorded weekly.  
Quantification of blood metabolites was performed using commercially available kits. 
 
Dual energy x-ray absorptiometry (Dexa) scan analysis.  Dexa scan analysis was 
performed with the ultra high-resolution densitometer PIXImus (GE Medical systems) 
allowing precise measurement of bone density and body composition (fat and lean mass).  
Bone mineral content and density and body composition were recorded on anesthetized 
mice. 
 
Histological analysis.  Liver tissues were prepared for cryosectioning and sections were 
stained with Oil Red O and hematoxylin.  Pancreas and adipose tissue were fixed in 4% 
formaldehyde and paraffin-embedded using a standard protocol.  Adipose tissue sections 
were prepared and stained with hematoxylin and eosin (H&E).  For islet size quantification 
pancreatic sections (8µm) were cut in regular intervals and sequential sections were stained 
with H&E.  All sections were photographed and the area of every islet was quantified using 
the ImageJ software.  In average, 40 islets per pancreas were analyzed.  For quantification 
of β cell mass, β cells were stained using rabbit antibodies against insulin and detected with 
a secondary antibody conjugated with horseradish peroxidase (Vectastain ABC kit, Vector 
Labs) followed by incubation in DAB peroxidase substrate solution and subsequent 
counterstaining with hematoxylin.  Images of the entire pancreatic section were obtained 
using a digital microscope (Coolscope, Nikon) and sections were analyzed using ImageJ 
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software.  The β cell mass was calculated by the percentage of β cell area and pancreas 
weight.  For immunofluorescence, pancreatic sections were stained for insulin and glucagon 
using rabbit antibodies against insulin and mouse antibodies against glucagon.  Immune 
complexes were detected with secondary antibodies conjugated with TexasRed or FITC, 
respectively. 
 
Glucose uptake into adipocytes.  Adipocytes were isolated from epididymal and inguinal 
fat pads by 60’ digestion in KRBH buffer containing 1% BSA and 1100U/ml collagenase.  
Cells were starved for an additional 60’ in KRBH buffer containing 1% BSA.  During the last 
30’ 100nM insulin was added.  To measure glucose uptake, isolated adipocytes were 
washed once in HBS buffer (140mM NaCl, 20mM Hepes pH7.4, 5mM KCl, 2.5mM MgSO4, 
1mM CaCl2) and incubated for 10’ in transport solution (HBS containing 10uM 2-deoxy 
glucose and 0.5uCi/ml 3H 2-deoxy glucose).  Cells were washed 3 times in cold PBS and 
radioactivity was measured by scintillation counter.  Glucose uptake was normalized to cell 
number, which was determined by qPCR on intronic DNA.  Primers used were 5’-
CTACAGATGTGGTAAAGGTCCGC-3’, 5’-GCAATGGTCTTGTAGGCTTCG-3’. 
 
Quantitative PCR.  Total RNA was isolated from frozen tissues using TriZOL reagent 
(Invitrogen).  3µg total RNA was reverse transcribed using Superscript II reverse 
transcriptase (Invitrogen) and random nonamers.  qPCR was performed using the power 
SYBR green mix (Applied Biosystems) and normalized to Polr2a expression. The following 
primers were used: Polr2a sense 5’-AATCCGCATCATGAACAGTG-3’, Polr2a antisense 5’-
CAGCATGTTGGACTCAATGC-3’; IGF1 sense 5’-GCTGCTGAAGCCATTCATTT-3’, IGF1 
antisense 5’-TTGCTCTTAAGGAGGCCAAA-3’. 
 
Statistical analysis.  All data are shown as mean ± s.e.m.  Statistical significance between 
two groups was determined using unpaired, two-tailed Student’s t-test. * P<0.05; ** P<0.01. 
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Figures and Tables 
 
 
 
 
Fig. II-1.   Adipose-specific rictor knockout mice have increased body weight. (A) Adipose-
specific rictor knockout mice (rictorad-/-) were generated using the Cre/LoxP system (see 
Experimental procedures).  (B) Immunoblot showing knockout of rictor and impaired 
mTORC2 signaling in adipose tissue of two littermates. A short (right) and long (left) 
exposure are shown.  Residual rictor protein in rictorad-/- in the long exposure is likely from 
stromal vascular cells in the adipose tissue that do not express aP2-Cre.  (C) Weight curves 
of rictorfl/fl (n=16) and rictorad-/- (n=14) male mice 8 to 18 weeks of age maintained on a chow 
diet.  (D) Weight curves of rictorfl/fl and rictorad-/- male mice fed a HFD for 10 weeks (n=10 per 
genotype).  (E) Body length determined by measuring nasal-to-anal distance.  Mice were put 
on HFD at the age of 8 weeks. Values in D - F are mean ± s.e.m.  *P<0.05; **P<0.01, rictorad-
/- vs. rictorfl/fl. 
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Fig. II-2.   rictorad-/- mice have increased lean mass. (A and B) Lean mass (A) and fat 
mass (B) in rictorfl/fl and rictorad-/- mice was determined by dexa scan analysis.  Mice were 
maintained on a chow diet or fed a HFD for 6 weeks (n=6-8 per group).  (C – J), Weight of 
individual organs.  Individual organs were excised and weighed.  Mice were maintained on a 
chow diet or fed a HFD for 10 weeks.  Bone mineral content was determined by dexa scan 
analysis as in (A) and (B).  Values in (A – J) are represented as mean ± s.e.m (n=11-27 per 
genotype; n=5 in (F)). *P<0.05; **P<0.01, rictorad-/- vs. rictorfl/fl.  
 
 
 
 
 
 
 
Fig. II-3.  rictorad-/- mice have unaltered adipose tissue morphology and increased 
hepatic steatosis.  (A) Representative image of H&E stained sections of epididymal fat.  (B) 
rictorad-/- and rictorfl/fl develop hepatic steatosis after HFD. Representative image of liver 
sections stained with Oil Red O and hematoxylin.  (C) Quantification of liver triglycerides in 
mice fed a chow diet (n=4 per group) or a HFD for 10 weeks (n=16 per group). 
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Fig. II-4.  rictorad-/- mice are hyperinsulinemic.  (A and B) Blood glucose from overnight 
fasted or fed mice either on chow diet (A) or HFD for 10 weeks (B) (n=10-15).  (C and D) 
Blood insulin form overnight fasted or fed mice either on chow diet (C) or HFD for 10 weeks 
(D) (n=10).  (E) Quantification of average islet area represented in arbitrary units (AU). n=3-5 
per group.  (F) Representative image of an islet in rictorfl/fl and rictorad-/- mice immunostained 
for insulin (red) and glucagon (green).  Nuclei were stained with DAPI (blue).  Images were 
taken at the same magnification and islets are shown at the same scale.  (G) Quantitative 
analysis of β cell mass of rictorfl/fl and rictorad-/- mice on chow diet. 
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Fig. II-5.   rictorad-/- mice have improved glucose tolerance after HFD.  (A and B) Glucose 
tolerance tests in overnight-starved mice fed a chow diet (A) or HFD for 10 weeks (B).  Mice 
were injected with glucose (2g/kg, i.p.) and blood glucose was subsequently measured at the 
indicated time points (n=10-16).  *P<0.05, **P<0.01, rictorad-/- vs. rictorfl/fl. n=9-10 per group.  
(C) Insulin sensitivity test in fed mice on a chow diet. Mice were injected with insulin 
(0.75IU/kg, i.p.) and blood glucose was subsequently measured at the indicated time points 
(n=10-11, P>0.05).  (D)  Immunoblot of in vivo insulin stimulated adipose tissue and muscle.  
21-week old mice fed a chow diet were starved over night and aneasthesized, followed by 
i.p. injection of saline or 150mU/g body weight insulin.  After 15 minutes adipose tissue, 
muscle and liver were removed and snap frozen.  Lysates were run on a SDS-PAGE and 
immunoblotted for phosphorylated and total Akt, and phosphorylated and total GSK3.  (E)  
Basal and insulin-stimulated glucose uptake was measured on isolated adipocytes from 
rictorfl/fl and rictorad-/- mice on chow diet.  Glucose uptake was normalized to cell number and 
data are shown in arbitrary units (n=5).  
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Table II-1.  Blood metabolites.  Clinical chemistry and hormone values of mice fed a chow 
diet or HFD for 10 weeks.  Values are mean ± s.e.m (n=9-10 per group) *P<0.05, **P<0.01. 
 
Fig. II-6.  rictorad-/- mice have elevated levels of 
IGF1.  (A) Blood IGF1 levels in mice fed a chow 
diet or HFD for 10 weeks.  (B) IGF1 mRNA 
expression in adipose tissue (epididymal) and liver 
of mice fed a chow diet was determined by 
quantitative RT-PCR.  IGF1 expression was 
normalized to Polr2a expression and is shown in 
arbitrary units (AU).  (C and D) IGFBP3 (C) and 
GH (D) levels were determined in mice fed a chow 
diet or HFD for 10 weeks.  Values in (A – D) are 
represented as mean ± s.e.m.  *P<0.05; **P<0.01, 
rictorad-/- vs. rictorfl/fl (n= 8-10).  (E) Model of 
adipose mTORC2 regulating whole body growth.  
Adipose mTORC2 negatively regulates IGF1 and 
insulin production by liver and pancreas, 
respectively, and thereby controls systemic growth 
and metabolism. 
Results – Part 1 52 
Supplementary data 
 
 
 
 
Fig. II-S1.  Immunoblot showing specific knockout of rictor in adipose tissue but not in other 
tissue examined. 
 
 
 
 
 
 
Fig. II-S2.  Quantification of hepatic glycogen content in rictorad-/- and rictorfl/fl mice fed a chow 
diet (n=4 per group) or a HFD for 10 weeks (n=10 per group). 
A small piece of frozen liver tissue was dissolved at 95°C for 30 min in 0.3ml 0.5M KOH.  
25µl of 6% Na2SO4 and 750µl 100% MeOH were added to cooled samples.  Samples were 
incubated for 1h at -80°C and centrifuged at 14 000 rpm at 4°C for 5 min.  200µl of 2mg/ml 
amyloglucosidase in 0.2M sodium acetate buffer (pH 4.9) was added to the pellet for 60 min 
of incubation at 37°C.  10µl of sample was used for glucose assays (GAHK-20 kit, Sigma).  
Glycogen standard curve was prepared using glycogen (G1767, Sigma) dissolved in 0.5M 
KOH. 
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Fig. II-S3.  Glucose tolerance test in mice fed a chow diet (A and B) or HFD for ten weeks (C 
and D).  Mice were injected with glucose (2g/kg, i.p.) and blood glucose (A and C) and insulin 
(B and D) were simultaneously measured at the indicated time points. *P<0.05, **P<0.01, 
rictorad-/- vs. rictorfl/fl. n=9-10 per group. 
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Additional results 
 
As described in the manuscript above, we suggest that mTORC2 in adipose tissue 
negatively regulates IGF1 and insulin production by liver and pancreas, respectively.  One 
possibility how this regulation might occur, is that mTORC2 in adipose tissue may control 
expression and/or secretion of a factor(s) that in turn regulates these organs.  To address 
this point, we undertook global gene expression analysis to identify genes for which 
expression is altered in adipose tissue deficient for mTORC2.  We used the Affymetrix Gene 
Chip Mouse Gene 1.0 ST Array, which covers more than 28’000 genes.  Since the growth 
phenotype was more pronounced on a HFD, we limited the microarray analyses to 
epididymal adipose tissue RNA from rictorad-/- and rictorfl/fl mice (n=3) that were fed a HFD for 
10 weeks.   
We identified a set of 194 genes whose mRNA levels were upregulated at least 1.4-
fold in rictorad-/- mice compared to rictorfl/fl mice and expression of 71 of these genes was 
increased at least twofold.  mRNAs of 217 genes were downregulated at least 1.4-fold in 
rictorad-/- mice compared to rictorfl/fl mice, 33 of them at least twofold.  To be of further interest 
as a possible candidate, genes with altered expression should initially fulfill the following 
requirements: (1) Altered expression has to be validated by qPCR.  (2) Expression has to be 
altered on both diets since serum IGF1 and insulin levels were increased in rictorad-/- mice 
compared to rictorfl/fl mice on a chow and high fat diet.  (3) Genes with altered expression 
should encode for a secreted protein.   
Using the IPA Software we identified at least 12 genes that were upregulated and 5 
genes that were downregulated and encode for proteins with a defined location in the 
extracellular space.  Proteins of the extracellular space include proteins that are secreted into 
the circulation, as well as proteins that are constituents of the extracellular matrix.  We 
decided to validate by qPCR the mRNA levels of adiponectin and several other genes that 
encode for secreted proteins (Glipr1, Cilp, QPCT, RBP4, Retnla).  Independently of the third 
criteria, we also chose two genes that were shown to be involved in regulating adipose tissue 
and whole body energy metabolism (Cpe and KLB).  In addition, we decided to verify RBP7 
gene expression by qPCR, which encodes a cellular protein and is related to RBP4, which in 
turn contributes to insulin resistance.  RBP7 was the most strongly downregulated gene in 
the microarray data.  The selected genes and their function are listed in Table II-S1; 
information was obtained from the Biobase proteome database.  
The microarray data revealed a 1.5-fold decrease in adiponectin mRNA levels.  This 
decrease correlated well with the observed decrease in serum adiponectin levels in rictorad-/- 
mice compared to rictorfl/fl mice described in the manuscript above and, thus, was a good 
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initial control for the validation of the microarray dataset.  The decrease at the transcriptional 
level could be confirmed by qPCR in rictorad-/- mice compared to rictorfl/fl mice on a HFD (Fig. 
II-S4).  However, on a chow diet mRNA levels were not significantly decreased, despite 
decreased serum levels, indicating that it is more difficult and not as straightforward to 
predict a correlation between the data obtained by microarray analysis and changes in the 
level of a secreted factor.   
Regarding the other genes that we chose for further validation by qPCR, altered 
mRNA expression was confirmed for nearly all genes on mice fed a HFD.  However, on a 
chow diet, mRNA expression of only one gene was significantly altered.  RBP4 mRNA levels 
were significantly decreased in rictorad-/- mice compared to rictorfl/fl mice on both diets (Fig. II-
S4).  RBP4 is a retinol binding protein and it is the only specific transport protein for retinol 
(vitamin A) in the circulation that delivers retinol to tissues (Quadro et al., 1999).  More recent 
findings identified RBP4 as an adipokine that contributes to insulin resistance in obesity and 
type 2 diabetes (Yang et al., 2005).  As suggested by decreased mRNA expression, rictorad-/- 
mice would likely have decreased serum RBP4 levels and should therefore have enhanced 
insulin sensitivity.  However, rictorad-/- mice are slightly insulin resistant.  Furthermore, no 
growth phenotype was described in mice with a full body knockout of RBP4 (Quadro et al., 
1999), making it unlikely that this factor accounts for the elevated IGF1 and insulin serum 
levels in the rictorad-/- mice. 
 
Initial analysis of the microarray data revealed no promising candidate whose altered 
expression could account for altered levels of a secreted factor that could regulate IGF1 and 
insulin secretion.  However, a more profound and extended analysis of the data might be 
required, considering the fact, as mentioned above, that serum adiponectin levels are 
reduced on both diets, but only on a high fat diet this is manifested also at the transcriptional 
level.  This could also be true for many other genes, which would also not fulfill the 
requirements set at the beginning. 
  Even though the initial goal was to search for candidate genes that encode for 
secreted proteins, other genes appearing in the microarray dataset would also be of potential 
interest in further understanding the role of mTORC2 in regulating adipose tissue function.  
The IPA software allows the assignment of individual genes into biological function 
categories.  An mTORC2-deficiency in adipose tissue influenced transcription of genes 
participating mainly in cellular movement (60 genes), cell morphology (71 genes), lipid 
metabolism (43 genes) and small molecule biochemistry (66 genes), suggesting that 
mTORC2 might have further functions in adipose tissue in addition to the ones described in 
this work.  It should also be kept in mind that gene expression of most validated genes was 
altered only in rictorad-/- mice fed a HFD, but not in rictorad-/- mice fed a chow diet, suggesting 
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that mTORC2 in adipose tissue might be particularly important after a HFD challenge.  This 
is also supported by the more pronounced growth phenotype of rictorad-/- mice on a HFD.  
  
 
Table II-S1: Overview of genes and their function that were further analyzed by qPCR. 
Gene Description Fold 
change 
Function 
Glipr1 Glioma pathogenesis-
related 1 
+7.0 Secreted; plays a role in induction of apoptosis, 
regulates reactive oxygen species level, inhibits 
angiogenesis and promotes JUN kinase activity 
QPCT Glutaminyl-peptide 
cyclotransferase 
+2.8 Extracellular; binds to zinc ion, may play a role in 
protein modification process; human QPCT gene is 
associated with hypertension, pheochromocytoma, 
and papillary thyroid carcinoma; identified in an 
insulinoma cell line 
Cilp Cartilage intermediate 
layer protein nucleotide 
pyrophosphohydrolase 
+2.4 Secreted; human Cilp is a putative phosphoprotein 
phosphatase and is associated with osteoarthritis 
and lumbar disc disease  
Cpe Carboxypeptidase E +2.1 Sorting receptor of the secretory pathway; enzyme 
responsible for final proteolytic processing step of 
prohormone intermediates, gene mutation is 
associated with hyperproinsulinemia; increase in 
human CPE autoantibody correlates with diabetes 
mellitus type 1; Cpe knockout mice become obese 
at app. week 10, have impaired glucose tolerance 
and are insulin resistant 
Adipoq Adiponectin -1.5 Secreted; mediates glucose, cholesterol, and lipid 
metabolism; human ADIPOQ is associated with 
various cancers, diabetes, HIV infection, 
acromegaly, obesity, coronary, inflammatory, 
eating, and metabolic disorders 
RBP4 Retinol binding protein 4 -2.1 Secreted; a cofactor transporter that plays a role in 
vitamin transport and glucose and vitamin 
metabolism; human RBP4 is associated with 
obesity and type 2 diabetes; serum levels are 
elevated in insulin-resistant animals 
Retnla Resistin like alpha -2.5 Secreted; acts in protein synthesis, activation of 
MAPKK and PKB, regulates angiogenesis, cell 
differentiation and proliferation, macrophage 
activation, and vasoconstriction; reduced 
expression in adipose tissue of ob/ob and db/db 
mice 
KLB Klotho beta -2.9 Transmembrane protein; coreceptor protein that 
binds Fgfr1 and Fgfr4, plays a role in fibroblast 
growth factor receptor signaling pathway, Fgf21-
mediated glucose uptake, and Slc2a1 expression 
in adipocytes, acts as a cofactor for Fgf21 activity 
RBP7 Retinol binding protein 7 -4.0 Cellular; required for retinoid incorporation into 
milk, may play a role in maintaining normal retinoic 
acid homeostasis in the heart and cardiovascular 
system 
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Figure II-S4: qPCR analysis of genes that revealed altered expression in the 
microarray analysis.  mRNA expression of indicated genes in adipose tissue of rictorad-/- 
and rictorfl/fl mice fed a chow or high fat diet was determined by qPCR.  Expression levels 
were normalized to Polr2a expression and are shown in arbitrary units (AU).  The upper 
panel shows genes with increased expression in adipose tissue of rictorad-/- mice, the lower 
panel shows genes with decreased expression in adipose tissue of rictorad-/- mice. Values are 
represented as mean ± s.e.m.  *P<0.05; **P<0.01 (n= 8-10).  P-values refer to rictorad-/- vs. 
rictorfl/fl on the individual diets.  
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Supplementary Methods 
 
Microarray 
Tissue was homogenized in 1ml Trizol Reagent (Invitrogen) using a Mixer Mill MM 301 
(Retsch) in the presence of 3 stainless steel beads.  Isolated total RNA was furtherpurified on 
RNA Clean & Concentrator-5 columns (Zymo Research). 
Total RNA preparations were analyzed using an Agilent 2100 bioanalyzer.   
cDNA Target was synthesized, fragmented, biotin-labeled using the WT Target Labeling and 
Control Reagents (Affymetrix) starting from 270 ng total RNA according to the procedure 
described in the GeneChip Whole Transcript Sense Target Labeling Assay Manual, Version 
4 (Affymetrix).   A Nano-drop was used to determine all RNA and DNA concentrations.  On 
average 33 µg of cRNA from each reaction was obtained. For each sample 10µg was used 
to generate cDNA.  On average 7.2 µg of cDNA from each reaction was obtained.  For each 
sample 5.5 µg of cDNA was fragmented and the resulting fragments of approximately 40-70 
nucleotides were monitored with the Bioanalyzer using the RNA Nano 6000 Chip.  All 
synthesis reactions were carried out in 0.5ml tubes using a PCR maching to ensure the 
highest possible degree of temperature control.   
The hybridization cocktail (80ml) containing fragmented biotin-labeled target DNA at a final 
concentration of 25 ng/ml was transferred into Affymetrix Gene Chip Mouse Gene 1.0 ST 
Arrays (Affymetrix) and incubated at 45°C on a rotator in a hybridization oven 640 
(Affymetrix) for 17h at 60 rpm.  The arrays were washed and stained on a Fluidics Station 
450 by using the Hybridization Wash and Stain Kit using the Fluidics Procedure 
FS450_0007.  The GeneChips were processed with an Affymetrix GeneChip® Scanner 3700 
7G.  DAT image files of the microarrays were generated using Affymetrix GeneChip 
Command Console.  Data were initially analyzed using XRAY software (Biotique) and later 
with the IPA (Ingenuity Pathways Analysis) Software (Ingenuity Systems).  The IPA software 
allows the identification of biological networks, global functions and functional pathways of a 
particular dataset.  The dataset representing genes with altered expression profile derived 
from the microarray analysis was imported into the IPA tool.  The basis of the IPA program 
consists of the Ingenuity Pathway Knowledge Base, which is derived from known functions 
and interactions of genes published in the literature.  Each gene product is assigned to 
functional categories. Some genes may participate in multiple functions and therefore some 
redundancy exists in gene number.   
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qPCR 
Total RNA was isolated from frozen tissues using TriZOL reagent (Invitrogen).  3µg total 
RNA was reverse transcribed using Superscript II reverse transcriptase (Invitrogen) and 
random nonamers.  qPCR was performed using the power SYBR green mix (Applied 
Biosystems) and normalized to Polr2a expression. The following primers were used: Polr2a 
sense 5’-AATCCGCATCATGAACAGTG-3’, Polr2a antisense 5’-
CAGCATGTTGGACTCAATGC-3’; Glipr sense 5’-AACCGAGCATTCTATCAG-3’, Glipr 
antisense 5’-GAAGCCATCCAGACTATC-3’; Cpe sense 5’-GTGCTTTCTGCCAATCTG-3’, 
Cpe antisense 5’-CTGCTGTCATCGTCATTC-3’; Cilp sense 5’-
ATTGGCTCTATGAAATATCTCTG-3’, Cilp antisense 5’-AGGCTGGACTCTTCTCAC-3’; 
QPCT sense 5’-ACGACTTGAGACCATTGC-3’, QPCT antisense 5’-
AGGACCGATAGCCATAGG-3’; RBP4 sense 5’-GCAAGACAACATCATCGC-3’, RBP4 
antisense 5’-GAGAAAGGAGGCTACACC-3’; KLB sense 5’-ATGCCACATACTGCTTCC-
3’, KLB antisense 5’-GTAGTTATGCCACACTTTCG-3’; RBP7 sense 5’-
GTTACCTGGGAGAATGAC-3’, RBP7 antisense 5’-TGTTGCTGGAGATGTATC-3’; 
Retnla sense 5’-CCTCCACTGTAACGAAGACTCTC-3’, Retnla antisense 5’-
GCAAAGCCACAAGCACACC-3’ 
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Part 2:  mTORC2 is required for cell migration 
 
The following part describes the role of mTORC2 in cell migration.  In collaboration with my 
colleague Vittoria Zinzalla we have analyzed the role of mTORC2 in cell migration in two cell 
lines.  The first cell line is a mouse embryonic fibroblast (MEF) cell line with an inducible 
knockout of rictor.  The second cell line is a 3T3-NIH fibroblast cell line with an inducible 
overexpression of activated H-Ras, which will result in transformation of these cells.   
In this work, I have mainly generated and characterized the inducible MEF cell lines, while 
Vittoria Zinzalla has performed the experiments in the inducible H-Ras fibroblast cell line.   
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Abstract 
 
mTOR complex 2 is an essential kinase complex that is activated by growth factors and 
phosphorylates the kinases Akt and SGK1 at their hydrophobic motifs to fully activate them.  
mTORC2 is composed of mLST8, mSin1, rictor and the serine/threonine kinase mTOR.  
Upregulation of the mTOR signaling pathway is a common event in many tumors.  However, 
most cancer studies addressed the role of mTOR dysregulation using the drug rapamycin, 
which specifically inhibits mTOR that functions in mTOR complex 1.  Therefore, less is 
known about the role of mTORC2 in cancer biology.  Here, we have generated a new mouse 
embryonic fibroblast cell line bearing an inducible knockout of the mTORC2 essential 
component rictor (iRicKO).  Initial characterization of the cell line revealed that loss of rictor 
results in reduced cell proliferation.  Furthermore, we show that loss of rictor increases 
mTORC1 assembly and S6K phosphorylation and thereby leads to increased cell size.  To 
further investigate the role of mTORC2 in actin-dependent processes we analyzed cell 
motility and found reduced cell migration upon induction of rictor knockout.  This reduced 
migratory behavior is due to impaired activity of the RhoGTPase family members Rac1, 
Cdc42, and RhoA.  In addition, we also show that mTORC2 is upregulated and its activity is 
required for cell motility in H-Ras-transformed fibroblasts.  Therefore, we provide evidence 
for the role of mTORC2 in cell migration of normal and oncogenic cell lines suggesting an 
important function of mTORC2 in the development of cancer and metastasis.  
 
 
Introduction 
 
The mammalian Target of Rapamycin (mTOR) is an evolutionary highly conserved 
serine/threonine kinase that is centrally involved in the control of cell growth, proliferation and 
metabolism (Wullschleger et al., 2006).  mTOR is involved in several human diseases, 
including cardiovascular diseases, obesity, and diabetes, and it is estimated that 70% of 
human cancers are associated with malfunctions of the mTOR signaling pathway.   
mTOR functions in one of two distinct multiprotein complexes named mTOR complex 
1 (mTORC1) and mTORC2 (Jacinto et al., 2004; Loewith et al., 2002; Sarbassov et al., 
2004).  mTORC1 contains mTOR, mLST8 and raptor and is sensitive to the 
immunosuppressant and anti-cancer drug rapamycin.  mTORC1 is activated by nutrients, 
such as amino acids, growth factors, such as insulin, and responds to the cellular energy 
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status.  The most extensively studied function of mTORC1 is the regulation of translation via 
phosphorylation of S6 kinase and 4E-binding protein 1 (4E-BP1), but also autophagy, 
mitochondrial metabolism and transcription are regulated by mTORC1 (Soulard and Hall, 
2007).  mTORC2 contains mTOR, rictor, mLST8 and mSin1 and is resistant to direct 
rapamycin inhibition.  Growth factors can increase mTORC2 activity, but the underlying 
mechanism is yet unknown.  mTORC2 plays a fundamental role in controlling the activity of 
Akt/PKB and SGK1; it phosphorylates both kinases at their hydrophobic motif site - Akt at 
Ser473 and SGK1 at Ser422 (Garcia-Martinez and Alessi, 2008; Hresko and Mueckler, 2005; 
Sarbassov et al., 2005).   
mTORC2 plays an important role in the regulation of actin cytoskeleton dynamics 
(Jacinto et al., 2004; Sarbassov et al., 2004).  Knockdown of any component of mTORC2, 
including mTOR, mLST8, rictor and mSin1, causes a similar alteration of cell morphology 
and cell adhesion.  In addition, mTORC2 regulates protein kinase C α (PKCα) activity by 
regulating its phosphorylation and stability (Facchinetti et al., 2008; Ikenoue et al., 2008).  
PKCα plays an important role in cytoskeleton organization (Larsson, 2006).  However, the 
molecular mechanism by which mTORC2 controls actin cytoskeleton dynamics is not 
understood.  It was shown that cell movement and chemotaxis highly depend on TORC2 in 
Dictyostelium, a powerful model organism to study these two mechanisms (Kamimura et al., 
2008; Lee et al., 2005).  Loss of any component of TORC2 results in loss of speed, cell 
polarity and directionality, overall affecting chemotaxis.  Furthermore, it was shown that in 
Dictyostelium cytosolic Ras GTPases can activate TORC2 thereby leading to the activation 
of the PKBs, followed by several phosphorylation events on signaling proteins that regulate 
directed cell movement.  In this study, we have analyzed the role of mTORC2 in controlling 
cell migration in the inducible rictor knockout MEF cell line. Our data suggest that mTORC2 
promotes cell migration by maintaining the reciprocal balance between the RhoGTPases.  
Migration of tumor cells is a prerequisite for cancer cell invasion and metastases and 
the underlying signaling mechanisms are complex.  The role of the Ras signaling pathway in 
tumor initiation is well established, but whether and how it contributes to invasion and 
metastasis is not well understood (Campbell and Der, 2004; Furge et al., 2001).  Given the 
more aggressive and lethal phenotype for metastatic tumors, it is necessary to gain further 
knowledge on the signaling mechanisms that lead to tumor cell migration and subsequently 
to invasion and metastases.  A better understanding of these molecular mechanisms can 
lead to new approaches in the design of more effective therapies.  Ras-oncogenes are 
mutated in 30% of all human cancers leading to constitutively activated Ras GTPases that 
are insensitive to GAP stimulation (Barbacid, 1987; Bos, 1989).  One way how H-Ras, one of 
the ras genes, can regulate tumor metastasis is by increasing cell migration (Kim et al., 
2003b; Moon et al., 2000).  However, the signaling molecules implicated in these processes 
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have not been fully characterized.  In this study, we have analyzed the role of mTORC2 in 
oncogenic H-Ras-mediated cell migration.  Our findings suggest that H-Ras activates 
mTORC2, as detected by increased phosphorylation of Akt at Ser473, and that this complex 
is an important signaling intermediary in H-Ras-mediated cell migration. 
 
 
Results 
 
Generation of inducible raptor and rictor knockout MEF cell lines 
While the function of mTORC1 can be easily studied by rapamycin treatment, we lack an 
mTORC2 specific inhibitor and hence we rely on genetic manipulation to study the function of 
mTORC2.  To circumvent the rapamycin insensitivity of mTORC2 and obtain further insights 
into the TOR signaling branch mediated by mTORC2, we took advantage of the Cre/LoxP 
technology to generate inducible knockout mouse embryonic fibroblasts (MEFs) deficient for 
either the mTORC1-specific component raptor or the mTORC2-specific component rictor.  In 
contrast to a constitutive knockout MEF cell line the inducible system allows a very tight and 
temporal regulation of recombination and thereby resulting in a very efficient knockout.  
Furthermore, it allows us to study immediate changes upon loss of mTOR complex integrity 
and circumvents the possibility of cell adaptation.  Primary MEFs were isolated from mice 
homozygously floxed for raptor or rictor, respectively (Bentzinger et al., 2008; Polak et al., 
2008).  After immortalization with the simian virus 40 (SV40) large T antigen cells were 
infected with retroviruses carrying a tamoxifen-inducible Cre recombinase (CreERT2) and 
selected for stable integration (Fig. III-1A).  CreERT2 is a fusion protein of a mutated 
estrogen receptor to the Cre recombinase, which remains in an inactive form within the cell 
(Feil et al., 1996; Leone et al., 2003).  Only upon addition of the synthetic estrogen receptor 
ligand 4-hydroxytamoxifen (4-OHT) CreERT2 is activated, thereby allowing temporal control 
of gene recombination that leads to the knockout of the gene of interest.  The resulting MEF 
cell lines bearing an inducible raptor or rictor knockout were named iRapKO and iRicKO, 
respectively.   
Time course analysis of 4-OHT addition to the cell lines revealed that rictor or raptor 
proteins were no more detectable after 3 days of 4-OHT treatment (Fig III-1B).  Therefore, for 
all subsequent experiments cells were pre-treated with 4-OHT for at least 3 days.  Control 
cells without CreERT2 (control) were used to exclude any 4-OHT-induced effect that was not 
related to the induction of the knockout of rictor or raptor.   
To verify that loss of either raptor or rictor in our cell system results in the expected 
changes within the mTOR signaling pathway, we analyzed the downstream targets of the 
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mTORC1 and mTORC2 signaling branches upon insulin stimulation.  Loss of rictor results in 
a strong reduction of Akt Ser473 phosphorylation that also leads to a decrease in 
phosphorylation of FoxO1/3a, two Akt substrates, whose phosphorylation is affected when 
Akt is not phosphorylated at the hydrophobic motif (Guertin et al., 2006) (Fig III-1C).  In 
agreement with previous findings loss of mTORC2 activity also leads to a decrease in PKCα 
protein levels (Facchinetti et al., 2008; Guertin et al., 2006; Jacinto et al., 2006).  As 
expected, in 4-OHT-treated iRicKO cells mTORC1 activity and its downstream signaling 
remain unaffected upon insulin stimulation as observed by unchanged S6K phosphorylation.  
Furthermore, 4-OHT alone has no effect on the mTOR signaling pathway in control cells.  
4-OHT treated iRapKO cells show a strong reduction in S6K Thr389 phosphorylation, 
as well as an increase in Akt Ser473 phosphorylation, confirming the specific loss of 
mTORC1 activity in iRapKO cells (Fig III-1D).  The observed increase in Akt Ser473 
phosphorylation is due to loss of the negative feedback loop that normally inhibits upstream 
signaling by the insulin pathway during prolonged stimulation of mTORC1 and S6K 
(Harrington et al., 2004; Shah et al., 2004; Um et al., 2004).  Therefore, loss of mTORC1 or 
mTORC2 signaling in induced iRapKO or iRicKO cells, respectively, correlates well with 
findings from other cell systems where mTORC1 or mTORC2 activity was diminished.  This 
allows us to use these cell lines to further study the functions of mTORC1 and mTORC2.  In 
the following we have mainly continued on further characterizing the iRicKO cells. 
 
Loss of rictor impairs cell proliferation 
We determined whether loss of rictor in our cell system affects cell proliferation by comparing 
growth rates of untreated iRicKO cells and iRicKO cells pre-treated with 4-OHT for 3 days to 
induce rictor knockout.  Equal number of cells were seeded and counted daily for 6 days.  
Non-induced iRicKO cells proliferated more rapidly than induced iRicKO cells (Fig. III-2A).  4-
OHT alone had no effect on proliferation of control cells.  Consistently, the population 
doubling (PD) of each group after 6 days confirmed the differences in growth rates shown by 
daily counts.  PD for induced iRicKO cells was reduced by 30% as compared to untreated 
iRicKO cells, while untreated and 4-OHT-treated control cells showed exactly the same PD.  
To further examine the reduced proliferation rate in rictor knockout-induced iRicKO cells we 
analyzed the cell cycle distribution under normal growth conditions measuring the DNA 
content by flow cytometry.  Loss of rictor resulted in an alteration in cell cycle distribution, 
with 45% of the cells arrested at G1/G0 phase while only 36% of untreated iRicKO cells were 
found in G1/G0 phase (Fig. III-2B).  Furthermore, treatment with 4-OHT for 6 days, 
resembling a long-term loss of rictor, increased the ratio of cells arrested at G1/G0 phase 
(65%) even further.  Therefore, rictor is required for normal cell proliferation. 
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Loss of rictor results in increased cell size and S6K phosphorylation. 
While cell proliferation was impaired in rictor knockout-induced iRicKO cells due to an 
increase in G1/G0 arrest we furthermore found by FACS analysis that rictor-deficient iRicKO 
cells, under normal growth conditions, were increased in cell size as measured by the 
forward scatter distribution (Fig. III-2C).  Increased cell size was apparent after 3 days of 4-
OHT treatment and became even more obvious after 6 days of 4-OHT treatment.  Increased 
cell size is indicative of increased cell growth that is mainly regulated by mTORC1 via S6K 
phosphorylation.  Therefore, we closer analyzed S6K phosphorylation at the mTORC1 site 
Thr389 under normal growth conditions after loss of rictor in the iRicKO cells.  3 days after 
induction with 4-OHT there was a small but significant increase in basal S6K Thr389 
phosphorylation, and this increase became even more apparent after 4 or 6 days of 4-OHT 
treatment (Fig. III-2C).  The observed increase in S6K phosphorylation suggested an 
increase in mTORC1 activity.  Since in rictor-deficient cells mTORC2 cannot be formed, we 
assumed that this could lead to an increase in mTORC1 assembly.  To investigate this 
hypothesis we have treated iRicKO cells with or without 4-OHT for 6 days and subjected the 
cell extracts to immunoprecipitation with an anti-mTOR antibody.  In untreated cells, raptor 
and rictor co-immunoprecipitated with mTOR, while in rictor deficient cells only raptor co-
immunoprecipitated with mTOR.  Furthermore, raptor binding to mTOR was clearly increased 
in 4-OHT treated cells compared to untreated cells (Fig. III-2D).  Overall, we found that under 
normal growth conditions induction of rictor knockout increases mTORC1 assembly leading 
to increased S6K Thr389 phosphorylation and cell size.  
 
Loss of rictor inhibits cell migration and affects RhoGTPase activity 
Regulation of the actin cytoskeleton by mTORC2 has been described (Jacinto et al., 2004; 
Sarbassov et al., 2004); and, moreover, recent findings in Dictyostelium show the 
involvement of TORC2 in controlling cell polarity and chemotaxis (Kamimura et al., 2008; Lee 
et al., 2005).  Therefore, we investigated the role of mTORC2 in directed cell migration in the 
iRicKO cells.  We first treated the cells with 4-OHT for 3 days and then performed serum-
induced transwell assays to determine cell motility.  Induction of rictor knockout showed a 
significant decrease (app. 70%) in the number of migrating cells when stimulated with serum 
(Fig. III-3A).  In contrast, 4-OHT did not impair serum-induced migration of control cells.  This 
suggests that mTORC2 is involved in the regulation of cell motility. 
The Rho family of GTPases, including Cdc42, Rac1 and RhoA are critical regulators 
of cell polarization and directional migration.  The balance between the activity of these small 
GTPases determines the migratory behavior in fibroblasts (Fukata et al., 2003).  Initial 
studies on the characterization of mTORC2 suggested the involvement of this complex in 
regulating the formation of active, GTP-bound Rac1 (Jacinto et al., 2004).  Therefore, we 
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analyzed whether mTORC2 regulates serum-mediated cell migration in the iRicKO cells 
through signaling to the Rho family GTPases Cdc42, Rac1 and RhoA.  After induction of 
rictor knockout with 4-OHT for 3 days we detected the activity of Cdc42, Rac1 and RhoA in 
serum-stimulated cells using pull down assays.  Briefly, a fusion protein of glutathione-S-
transferase (GST) and the CRIB domain of the Rac1/Cdc42 effector molecule PAK only 
allows binding of the activated, GTP-loaded Rac1/Cdc42.  Similar, the Rho binding domain of 
the Rho effector Rhotekin fused to GST was used to pull down activated, GTP-bound RhoA.  
As expected, we observed that 4-OHT treatment alone did not affect Cdc42, Rac1 and RhoA 
activity in the control cells (Fig. III-3B).  In contrast, rictor knockout significantly decreased 
the levels of GTP-bound Rac1 and Cdc42 after 5 min (Fig. III-3B) and 10 min (data not 
shown) of serum-stimulation, suggesting that mTORC2 is required for their activation.  Since 
growth factor-induced Rac1 and Cdc42 activation has been shown to down-regulate RhoA in 
fibroblasts (Sander et al., 1999), we also analyzed RhoA activity by measuring the amount of 
GTP-bound RhoA after 5 min (Fig. III-3B) and 10 min (data not shown) of serum-stimulation.  
Induction of rictor knockout increased RhoA activity, while at the same time decreasing 
Cdc42 and Rac1 activity, suggesting that mTORC2 is required to inhibit RhoA in cells 
stimulated with serum.  All together these data suggest that in the absence of mTORC2 the 
reciprocal balance between Cdc42/Rac1 and RhoA activities is lost, leading to an impaired 
migratory behavior in the MEFs. 
 
mTORC2 activity is involved in oncogenic Ras induced cell migration.  
The guanine nucleotide-binding protein Ras acts as a molecular switch connecting 
extracellular signals with a complex network of intracellular signal transduction pathways that 
mediate a variety of cellular responses including proliferation and differentiation (Karnoub 
and Weinberg, 2008).  The three Ras proto-oncogenes, H-, N- and K-Ras, are amongst the 
most commonly mutated genes in all human cancers.  In fact, mutational activation of Ras 
proteins promotes oncogenesis by disturbing a multitude of cellular processes, such as gene 
expression, cell cycle progression and cell proliferation, as well as cell survival and cell 
migration.  Key steps in invasion and metastasis include alterations in cell adhesion, cell–
matrix and cell–cell interactions, and the acquisition of an increased migratory phenotype.  
These cellular properties are regulated, in part, by Rho family GTPases and their control of 
actin organization.  The aberrant activities of Rho GTPases have been implicated in 
contributing to a metastatic and invasive phenotype (Sahai and Marshall, 2002; Schmitz et 
al., 2000).  The induction of cell migration through Ras has been shown to be critically 
dependent on Rho GTPase function (Zohn et al., 1998). 
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In the previous part we have shown that induction of rictor knockout inhibits cell 
migration and affects RhoGTPase activity. These data suggest a link between the Ras and 
mTORC2 signaling pathways in regulating cell migration behavior.  
To investigate whether mTORC2 signaling is directly affected by Ras mutation, we 
analyzed Akt Ser473 phosphorylation in NIH3T3 fibroblasts harboring a tetracycline-inducible 
expression of a constitutively active mutant of H-Ras (NIH3T3/tet-on/H-RasG12R) (Park et 
al., 2006).  The expression of H-RasG12R was detectable 6 h after addition of doxycycline 
and remained highly elevated for at least 72 h (Fig III-4A).  The phosphorylation of the Ras 
downstream effector Erk1/2 (Thr202/Thr204), as well as the phosphorylation of Akt Ser473 
were both increased within 6 h of doxycycline addition.  In agreement with the role of 
oncogenic H-Ras in cell transformation (Park et al., 2006), the cells underwent morphological 
transformation between 2 and 3 days after addition of doxycycline (data not shown).  To 
verify that mTORC2 is responsible for the phosphorylation of Akt at Ser473 after induction of 
oncogenic H-Ras, we analyzed the effect of rictor knockdown in NIH3T3tet-on/H-RasG12R 
cells pre-treated with doxycycline for 3 days.  As shown in Fig. III-4B, siRNA-mediated 
knockdown of rictor strongly reduced the level of Akt Ser473 phosphorylation.  These data 
establish that the increased Akt phosphorylation at Ser473 in cells expressing H-RasG12R 
depends on rictor and suggest that the mTORC2 signaling pathway is activated by the 
induction of oncogenic H-Ras. 
Next, we investigated the role of mTORC2 in the control of cell migration in the 
inducible oncogenic H-Ras fibroblasts (NIH3T3tet-on/H-RasG12R) using two different cell 
motility assays.  As shown by the wound healing assay, we found that in cells pre-treated 
with doxycycline for 3 days to induce oncogenic transformation, rictor knockdown 
significantly inhibited cell motility (Fig. III-5A).  To confirm the inhibition of cell migration upon 
loss of mTORC2, we performed the Transwell assay.  As expected, we observed that 
doxycycline treatment for 3 days increased serum-stimulated cell migration by 4 fold, which 
is in agreement with the role of oncogenic H-Ras in inducing cell migration.  In contrast, a 
significant inhibition of cell migration was observed upon knockdown of rictor in oncogenic 
transformed cells (Fig. III-5B).  Reduced expression of rictor and decreased phosphorylation 
of its substrate Akt at Ser473 in cells expressing siRNA was confirmed (Fig. III-5B).   
As shown in Fig III-3B, induction of rictor knockout in the iRicKO cells inhibits cell 
migration and affects the activity of the RhoGTPases Rac1, Cdc42, and RhoA.  Furthermore, 
properly activated RhoGTPases are required for the induction of cell migration through Ras.  
Since mTORC2 is required for the activation of cell migration by oncogenic H-Ras 
expression, this suggests that mTORC2 also regulates RhoGTPase activity in transformed 
NIH3T3tet-on/H-RasG12R cells.  Therefore, we analyzed Rac1 activity in these cells upon 
rictor knockdown.  In agreement with the findings in the iRicKO cells, knockdown of rictor in 
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NIH3T3tet-on/H-RasG12R cells pre-treated with doxycycline for 3 days caused a significant 
decrease in the level of GTP-bound Rac1 after 10 min of serum-stimulation (Fig. III-5C).  
Taken together, these data show that mTORC2 signaling plays an important role in the 
activation of RhoGTPases and cell migration by oncogenic H-Ras expression.  
  
 
Discussion 
 
Our data suggest that mTORC2 promotes cell migration by maintaining the reciprocal 
balance between Cdc42/Rac1 and RhoA activities in MEFs.  Furthermore, we show that in 
fibroblasts transformed with oncogenic H-Ras the observed increases in Akt Ser473 
phosphorylation and cell migration depend on mTORC2.  To investigate the role of mTORC2 
in cell migration we generated an inducible rictor knockout MEF cell line (iRicKO).  Initial 
characterization of these cells under normal growth conditions revealed that upon loss of 
rictor, iRicKO cells showed decreased proliferation but increased cell size.  The observed 
increase in cell size correlated with elevated S6K Thr389 phosphorylation and mTORC1 
assembly.  Currently, the mechanisms that regulate the formation of individual TORCs are 
unknown.  Recent data suggest that under steady-state conditions, rictor and raptor 
associate with mTOR at near stoichiometric levels and that the ratios of rictor or raptor bound 
to mTOR seem to be inversely related in different cell lines (Sarbassov et al., 2005).  
However, in previous studies siRNA-mediated knockdown of rictor did not seem to 
significantly influence the amount of raptor subsequently associated with mTOR (Sarbassov 
et al., 2006).  Our data, using the inducible system, are consistent with a balance between 
the two complexes: under normal growth conditions the induction of rictor knockout releases 
mTOR from mTORC2 and makes mTOR available to interact with raptor, thereby enhancing 
mTORC1 activity and cell growth. Therefore, our inducible knockout system appears to be 
more appropriate to study dynamic changes in mTOR signaling upon loss of rictor, as 
compared to cells with constitutive knockout of rictor or knockdown-mediated reduction in 
rictor protein levels.  
Using the iRicKO cells we could show that loss of rictor inhibits cell migration and 
affects RhoGTPase activity.  Consistent with our data, previous reports have shown that 
mTORC2 regulates the actin cytoskeleton through the GTPase Rac1 (Hernandez-Negrete et 
al., 2007; Jacinto et al., 2004).  Furthermore, a recent study has identified the regulation of 
Rac1 activity by mTORC2 as an important mediator of PGE2 – induced endothelial cell 
migration (Dada et al., 2008).  In this study, we identified the molecular mechanism involved 
in mTORC2-mediated cell migration.  Loss of rictor leads to a decrease in Cdc42/Rac1 
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activity and a simultaneous increase in RhoA activity upon serum stimulation.  One of the 
major determinants of cell motility in fibroblasts is the correct reciprocal balance between 
Cdc42/Rac1 and Rho activities (Sander et al., 1999), and we have demonstrated that 
mTORC2 is required for the correct balance between the increased Cdc42/Rac1 activity and 
consequent RhoA inhibition.  Consequently, the loss of this balance determines the impaired 
migration behavior in our rictor-deficient MEFs.   
To investigate a potential role of mTORC2-dependent cell migration in cancer cells 
we went on to show that mTORC2 is indeed required for cell migration in fibroblasts 
transformed with oncogenic H-Ras.  Ras interacts with and regulates multiple downstream 
effectors that stimulate diverse cytoplasmic signaling activities required for induction of cell 
migration.  One of the most commonly studied signal transduction routes downstream of 
oncogenic Ras activation is the PI3K pathway (Rodriguez-Viciana et al., 1997).  However, 
the PI3K-dependent molecular mechanism that leads to increased cell motility is not well 
understood.  It was shown that PI3K can activate Rac GEFs to promote the activation of the 
small GTPase Rac1, leading to increased cell migration (Han et al., 1998; Nimnual et al., 
1998).  Our data also show that mTORC2, whose activity has been shown to be PI3K-
dependent (O'Reilly et al., 2006), is required in oncogenic H-Ras mediated activation of cell 
motility and that RhoGTPases are affected in the absence of mTORC2.  H-Ras mediated 
activation of cell motility is only partially rescued by rictor knockdown.  This could be 
explained since H-Ras also activates the other complex of mTOR, mTORC1, as reported 
previously (Shaw and Cantley, 2006).  In fact, our unpublished data and findings by others 
support a role for mTORC1 in cell migration that was shown to be dependent on protein 
synthesis via the 4E-BP1/eIF4E and S6K pathways (Liu et al., 2006).  Overall, we suggest 
that mTORC2 can play an important role in the control of Ras-mediated tumor invasion and 
metastasis through the control of cell migration.  Consistent with our findings in the inducible 
oncogenic H-Ras expressing cell line, recent reports have emphasized the role of mTORC2 
in cell motility in tumors.  Increased mTORC2 activity promotes glioma migration and 
invasiveness and rictor is required for elevated levels of phosphorylated Akt Ser473, which 
correlated with increased anchorage-independent growth and migration (Masri et al., 2007). 
Moreover, a recent study by Qiao et al. showed that mTORC2 activity regulates the 
metastatic potential of a series of human breast cancer cell lines that derived from 
successive biopsies from a single patient (Qiao et al., 2007).   
 Overall, our findings point out the importance of mTORC2 activity in cell migration, in 
particular in oncogenic H-Ras-transformed cells.  We could show that mTORC2 is an 
important mediator of the Ras signaling pathway and is required at least for some of its 
oncogenic functions.  The high frequency of cancers with elevated Ras signaling, as well as 
the generally lethal phenotype resulting from cancer spreading and metastases, emphasizes 
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the importance of continuously improving the design of more effective therapies.  The role of 
mTORC2 in cancer only starts to be solved and mTORC2 could evolve into a potential drug 
target in the treatment of tumor invasion and metastasis.   
 
 
Materials and Methods 
 
Cell culture and transfections 
NIH3T3tet-on/H-RasG12R cells were obtained from Young Yil Bahk (Park et al., 2006). The 
expression of H-Ras was induced by treatment of the cells with doxycycline (2µg/ml) for the 
indicated periods of time.  All cell lines used were cultured in Dulbecco’s-modified Eagle 
medium (DMEM, 4500mg/l glucose) supplemented with 10% fetal bovine serum (FBS).  For 
experiments where cells were deprived of serum, cells were washed with phosphate-buffered 
saline, and incubated in serum-free DMEM.  For restimulation experiments, cells were 
serum-starved for 3 hours and then treated with DMEM containing 100 mM insulin for 30 
minutes.  Cells were harvested with lysis buffer that contained 50 mM Tris pH 8.0, 150 mM 
NaCl, 0.5 mM EDTA, 1% (v/v) Triton-X-100, supplemented with protease inhibitor cocktail 
(Roche).  Lysates were incubated for 30 minutes at 4°C, then cleared by a spin at 1000 g for 
5 minutes.  Supernatants were collected and used for immunoblots. Transfections with rictor 
and control siRNA were performed as described (Jacinto et al., 2004).  
 
Generation of iRicKO and iRapKO, inducible Rictor and Raptor knock out MEF cell 
lines. 
Mouse embryonic fibroblasts (MEFs) were isolated from either rictorloxP or raptorloxP mouse 
embryos at E12.5 and grown in DMEM supplemented with 10% FBS.  60mm dishes with 
primary cells were transfected with 2mg of a plasmid expressing simian virus 40 (SV40) large 
T antigen (kindly provided by Dr. David Ron; New York University School of Medicine. New 
York, USA).  Immortalized MEFs were infected for 48h with retroviruses carrying a 
tamoxifen-inducible Cre recombinase (CreERT2) in the presence of 5mg/mL polybrene 
(Sigma).  MEFs with stable integration of CreERT2 were subsequently selected in the 
presence of 3mg/mL puromycin (Sigma).  The resulting cell lines allowing inducible Rictor or 
Raptor knock out were named iRicKO and iRapKO, respectively.  Immortalized MEFs that 
were not infected were used as controls.  Cells were treated for at least 3 days in the 
presence of 1mM 4-hydroxytamoxifen (4-OHT; Sigma) to induce Rictor or Raptor knockout. 
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Cloning and retroviral production 
Retroviruses were produced by transfection of the ecotropic Phoenix packaging cell line with 
pMSCV vector.  The CreERT2 fragment was cloned from pCDNA3-CreERT2 (kind gift from 
Dr. Patrick Matthias; Friedrich-Miescher-Institute, Basel, Switzerland) into pMSCVpuro using 
EcoR1 restriction sites. 
 
Immunoblotting 
Protein extracts were resolved on SDS-PAGE and transferred to nitrocellulose membranes 
(Whatman). Immunoblots were performed using the following antibodies: rictor, raptor, Akt 
pS473, FoxO3a pT32/FoxO1 pT24, FoxO3, PKCα, S6K, S6K pT389, S6, S6 pS235/236 
(Cell Signaling); RhoA, H-Ras, PKCα pS657, ERK1/2, ERK1/2 pT202/Y204 (Santa Cruz); 
actin (Chemicon); Cdc42 (Pierce) and Rac1(Upstate). 
 
Immunoprecipitation 
mTOR immunoprecipitations were performed as described previously (Jacinto et al., 2004). 
 
Cell proliferation assay and flow cytometry 
50’000 cells that were either pre-treated or not with tamoxifen for 3 days were plated in 
duplicate in 60 mm dishes and cultured for up to 6 days under normal growing conditions.  
Cells were counted daily to establish growth curves.  The number of population doublings 
(PD) is calculated as follows: PD=ln(Nf/Ni)/ln2, where Nf and Ni are final and initial cell 
numbers, respectively. 
Cell cycle distribution and cell size were analysed by flow cytometry (Becton Dickinson FACS 
Calibur).  MEFs were harvested and stained with propidium iodide (PI) and cells were 
analysed for cell cycle distribution. Cell size was determined by measuring the forward 
scatter distribution.  
 
Wound healing assay 
Cells were cultured in six-well plates to reach confluence and then serum-starved for 24h.  
Wounds were introduced to the confluent monolayer of cells with a plastic pipette tip to 
generate a cleared scratch. The medium was changed to remove any floating or damaged 
cells.  The cells were incubated at 37°C, and cell movement into the wound area was 
photographed at different time points. 
 
Transwell assay 
Cell migration assays were performed using an 8-µm pore size Transwell system (Corning 
Inc., Corning, NY, USA).  Briefly, overnight serum-starved cells were trypsinized and 
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resuspended in serum-free DMEM at a density of 5 x 105 cells/ml. The top chamber of the 
Transwell was loaded with 0.1ml of the cell suspension, while the bottom chamber was 
loaded with 0.6ml DMEM containing 10%FBS.  After incubation at 37°C for 16h noninvasive 
cells on the upper surface of the membrane were removed with a cotton swab.  Cells that 
invaded were fixed with 4% paraformaldehyde, stained with crystal violet, and photographed.  
For quantification, the membranes were detached and solubilized in 10% acetic acid, and the 
intensity of the colored solution was quantified by spectrophotometrical analysis at 595 nm.  
 
Effector domain pulldown assays 
Rho, Rac, and Cdc42 activity were determined by pull down assays as described elsewhere 
(del Pozo et al., 2000; Ren et al., 2000). The pull down assays were performed with 
glutathione-agarose immobilized GST-Rhotekin (for RhoA) or GST-PAK1 (for Cdc42 or 
Rac1) effector domain.  Total lysates and bound proteins were analyzed by immunoblotting. 
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Fig. III-1.  Generation and initial characterization of iRapKO and iRicKO MEF cell lines.  A, 
Scheme illustrating the generation of the inducible raptor and rictor knockout MEF cell lines, 
which were named iRapKO and iRicKO, respectively.  B,  Time course analysis of 4-OHT-
dependent loss of raptor and rictor protein levels.  Cells were treated up to 3 days with 4-
OHT and protein levels were analysed by Immunoblot.  C,  Immunoblot analysis of the insulin 
stimulated mTOR signaling pathway after the induction of rictor knockout.  Cells were serum 
starved only or starved and restimulated with insulin for 30 minutes.  D,  Immunoblot analysis 
of the insulin stimulated mTOR signaling pathway after the induction of raptor knockout.  As 
C. 
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Fig. III-2.  Induction of rictor knockout impairs cell proliferation and increases cell size.  A, 
Graphs representing growth curves of 4-OHT treated and untreated iRicKO and control cells.  
Cells were either pre-treated with 4-OHT for 3 days (dashed lines) or not (full lines) and then 
equal numbers of cells were seeded.  iRicKO cells (triangle) and control cells (circle) were 
counted daily to establish the growth curves.  B, Cell cycle distribution of untreated (day 0) 
and 4-OHT treated (day 3 and 6) iRicKO cells.  Cells were stained with propidium iodide (PI) 
and cell cycle distribution was analysed by flow cytometry.  Percentage of cells in G0/G1 
phase is given for each graph.  C,  Cell size analysis of untreated (day 0) and 4-OHT treated 
(day 3 and 6) iRicKO cells.  Cells were subjected to FACS analysis and cell size was 
determined by forward scatter distribution.  D,  Co-immunoprecipitation of raptor and rictor 
with mTOR.  iRicKO cells were treated with (+) or without (-) 4-OHT for 6 days and cell 
extracts were subjected to IP by an anti mTOR antibody.  Co-immunoprecipitated (IP mTOR) 
or total proteins (cell extract) were immunoblotted with specific antibodies to each of the 
TORC components and its signaling pathway.  Data are representative of 2-3 independent 
experiments.  
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Fig. III-3.  Induction of rictor knockout decreases cell motility and affects RhoGTPase activity.  
A,  Transwell assay of iRicKO and control cells pretreated with (+) or without (-) 4-OHT for 3 
days.  Equal numbers of serum starved cells were loaded on the top chamber of the 
transwell and allowed to migrate towards the serum (10%) containing medium in the bottom 
chamber for 16 h.  The infiltrated membranes were stained with crystal violet and quantified.  
A representative image of stained filters is shown in the upper panel.  B,  RhoGTPase activity 
assays of iRicKO and control cells pretreated with (+) or without (-) 4-OHT for 3 days.  GST-
pull downs were performed on cell extracts from serum-starved cells that were re-stimulated 
for 5 minutes.  To assess Cdc42/Rac1 and RhoA activation, GTP-loaded Cdc42/Rac1 and 
RhoA were isolated by pull-down with PAK-CRIB and Rhotekin-RBD fused to GST, 
respectively.  Immunoblot analysis of rictor, total and GTP-bound Cdc42, Rac1 and RhoA is 
shown.  
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Fig. III-4.  mTORC2 activity is elevated in fibroblasts transformed with oncogenic Ras.  A, 
Time course analysis of doxycycline-induced expression of H-RasG12R.  NIH3T3 fibroblasts 
harbouring a tetracycline-inducible expression of a constitutively active mutant of H-Ras 
(NIH3T3/tet-on/H-RasG12R) were treated with doxycycline for the indicated time points.  
Indicated protein and phosphorylation levels were analysed by immunoblotting.  B, 
Immunoblot analysis of NIH3T3/tet-on/H-RasG12R cells pre-treated with doxycycline for 3 
days and subsequently treated with siRNA against rictor. 
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Fig. III-5.  mTORC2 activity is required for oncogenic Ras induced cell migration.  A,  Wound 
healing assay of transformed NIH3T3/tet-on/H-RasG12R treated with control or rictor siRNA.  
Representative images at 0 and 7.5 h time points (upper panel) after applying the wound and 
quantification of relative cell motility (lower panel).  Bars are shown as mean ± SD.  B,  
Transwell assay of transformed NIH3T3/tet-on/H-RasG12R treated with control or rictor 
siRNA. A representative image of stained filters is shown in the upper panel.  The infiltrated 
membranes were stained with crystal violet and quantified (lower panel, left). Immunoblot 
anaysis is shown to confirm knockdown of rictor (lower panel, right).  C,  Rac1 activity assay 
of transformed NIH3T3/tet-on/H-RasG12R treated with control or rictor siRNA.  GST-pull 
down was performed on cell extracts from serum-starved cells that were re-stimulated for 10 
minutes.  Immunoblot analysis of rictor, total and GTP-bound Rac1 is shown.  
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The goal of this thesis was to get a better understanding of the in vivo and in vitro functions 
of mTORC2.   
 
 The first part of this thesis focused on studying the in vivo function of mTORC2 in 
mice.  Since a full body knockout of any mTORC2 component is embryonic lethal (Guertin et 
al., 2006; Jacinto et al., 2006; Shiota et al., 2006; Yang et al., 2006), we took advantage of 
the Cre/LoxP system that allows us to study mTORC2 function in individual tissues.  In this 
work, we have focused on elucidating the role of mTORC2 in adipose tissue and described 
the phenotypic characterization of adipose-specific knockout mice of the mTORC2-specific 
component rictor.  In the past years, adipose tissue has evolved as a highly metabolic tissue 
that plays an important role in regulating whole body energy metabolism.  mTORC2 signaling 
is activated upon insulin stimulation and adipose tissue is one of the most insulin-sensitive 
tissues in the body, strongly suggesting a role for mTORC2 in this tissue.  
 We could show that mTORC2 in adipose tissue is important in controlling whole body 
metabolism and furthermore, we observed an unexpected role for adipose mTORC2 in 
controlling full body growth.  The most surprising and striking phenotype was that rictorad-/- 
mice were heavier than control rictorfl/fl mice due to an increase in lean mass.  This 
phenotype was more pronounced on a HFD.  Increased body size most likely results from 
increased serum levels of IGF1 in rictorad-/- mice.  Furthermore, rictorad-/- mice were 
hyperinsulinemic, but glucose tolerant.  Since IGF1 is mainly secreted from the liver, and 
insulin is secreted from the pancreas, our findings suggest the existence of an mTORC2-
dependent adipose to liver/pancreas signaling axis that controls full body growth and 
metabolism.   
 In this work we did not yet succeed in identifying the signal that could derive from 
adipose tissue to regulate IGF1/insulin secretion from the liver/pancreas.  In a first approach, 
we speculated that mTORC2 in adipose tissue may control expression of a secreted factor 
that in turn regulates the liver/pancreas.  Therefore, we performed a global gene expression 
analysis on adipose tissue RNA from rictorad-/- and rictorfl/fl mice.  However, initial analysis of 
the data did not give any promising hit and a more profound and extended analysis of the 
data might be required.  Furthermore, in the first approach, our search was limited to a 
secreted protein factor, but might need to be extended also to a non-protein factor such as a 
lipid, since lipids were shown to regulate systemic metabolism, as well.  Dysregulation of lipid 
metabolism is a critical contributor to metabolic diseases (Ginsberg et al., 2006).  For 
example, chronically elevated plasma free fatty acids (FFAs) from the adipose tissue are 
linked with the onset of peripheral insulin resistance and hepatic steatosis and have a role in 
the pathogenesis of type 2 diabetes (Boden and Shulman, 2002; Ginsberg et al., 2006).  
Final conclusions & outlook 83 
More recently, a new class of hormones – lipokines – was identified in mice (Cao et al., 
2008).  Lipokines are adipose-derived lipid hormones that regulate systemic metabolism.  
Cao et al. identified C16:1n7-palmitoleate as a lipokine that improves insulin sensitivity in 
muscle and blocks fat accumulation in the liver.  Whether mTORC2 in adipose tissue also 
regulates production and secretion of a lipokine remains to be determined.  Interestingly, 
studies performed in yeast have shown that TORC2 regulates ceramide production (Aronova 
et al., 2008).  It would be of interest to perform a lipidomic analysis of lipids in the blood or 
adipose tissue itself of rictorad-/- mice and compare it to the lipid profile of rictorfl/fl mice.   
 
The second part of this thesis focused on investigating new in vitro functions of mTORC2.  
Previous studies in yeast and mammals have shown that TORC2 is important for the 
regulation of actin cytoskeletal dynamics (Jacinto et al., 2004; Sarbassov et al., 2004; 
Schmidt et al., 1996).  We have re-addressed this function of mTORC2 and studied its role in 
cell migration, a process that depends on a highly coordinated and dynamic actin 
cytoskeleton.  We could show in fibroblasts that cell migration highly depends on mTORC2 
and that mTORC2 regulates the activity of the main members of the RhoGTPase family, 
Rac1, Cdc42 and RhoA, which are critical regulators of the actin cytoskeleton.  Cell migration 
is a central process during embryogenesis.  However, developing mouse embryos lacking 
either one of the mTORC2 components rictor or mLST8 only die around midgestation, which 
occurs around embryonic day E10.5, but develop normal during the early steps of embryonic 
development such as gastrulation, neurulation, and formation of the cardiovascular system 
(Guertin et al., 2006; Shiota et al., 2006).  Since these morphogenetic processes involve 
coordinated and directional migration of cells, the observations in rictor and mLST8-deficient 
embryos rather suggest an mTORC2-independent regulation of cell migration during 
embryogenesis.   
 Cell migration is not only involved in physiological processes, such as 
embryogenesis, but also in pathophysiological processes, such as metastasis, which is the 
movement or spreading of cancer cells from one organ or tissue to another.  In this study, we 
have also investigated the role of mTORC2-mediated cell migration in tumor cells using a 
transformed fibroblast cell line that expresses oncogenic H-Ras.  Knockdown of rictor 
strongly affected cell migration in these cells and furthermore resulted in impaired activation 
of the RhoGTPase Rac1 upon serum stimulation, strongly suggesting a role for mTORC2 in 
tumor cell migration.  Our in vitro results suggest that mTORC2 could be a potential target for 
the treatment of cancer and metastasis, however, further studies are now required to confirm 
that mTORC2-mediated cell migration plays an important role in the progression of 
metastases also in vivo.   
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 To study cell migration in this work, we have generated an inducible rictor KO mouse 
embryonic fibroblast (MEF) cell line (iRicKO).  In parallel, we have also generated an 
inducible raptor KO MEF cell line (iRapKO), and initial characterization of both is described in 
this work.  The established cell lines are very powerful tools to study mTORC1 and mTORC2 
signaling independently and are advantageous over other systems that also result in 
downregulation of mTORC signaling.  The inducible knockout system is more efficient than a 
transient knockdown, which generally does not result in a complete loss of the protein.  
Furthermore, in contrast to a constitutive knockout MEF cell line, the inducible system allows 
a very tight and temporal regulation of recombination, resulting in a very efficient knockout, 
which allows to study immediate changes upon loss of mTOR complex integrity and 
circumvents the possibility of cell adaptation.  In addition, isolation of constitutive knockout 
MEFs requires that the embryos can develop at least to E10.5.  raptor or mTOR constitutive 
knockout MEFs do not exist, because raptor- or mTOR-deficient embryos die during early 
development at around E5.5- E7.0, which is too early for MEF isolation. 
The inducible cell lines might be very helpful in studying global changes upon loss of 
either raptor or rictor.  We have already performed a global gene expression analysis with 
iRicKO cells.  However, only very few genes showed an altered expression, strongly 
suggesting that mTORC2 does not directly control gene transcription.  The microarray 
analysis was performed on cells that were treated with tamoxifen for 3 days, resembling 
short-term loss of mTORC2.  It is possible that a longer treatment, resembling a long-term 
loss of mTORC2, would influence expression of more genes, but these changes would be 
likely more indirect.   
In addition to studying the mTORC1 and mTORC2-specific transcriptome, the 
inducible knockout MEFs could also be very helpful in studying the mTORC1 and mTORC2-
specific phosphoproteome, which could lead to the identification of new downstream 
effectors of the mTOR signaling pathway.   
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Appendix: Adipose mTORC1 controls energy 
homeostasis 
 
The following part describes the phenotypic characterization of an adipose-specific knockout 
of the mTORC1-specific component raptor in mice.  In parallel to my main projects described 
above, I also collaborated with my colleague Pazit Polak to develop the following project and 
plan the required experiments.  The experiments were mainly performed by Pazit Polak.   
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